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Abstract 
Multiple Myeloma (MM) is a hematologic malignancy that accounts for approximately 
1% of all adult cancers. This study investigated the impact of patient distance traveled to 
MM care sites, which was not considered in previous research on any disease-specific 
staging or prognostic schema despite evidence suggesting that distance impacts patient 
outcome. This study investigated the impact of patient distance from the site of care on 
survival outcomes using a group of 480 clinical trial participants. Andersen’s behavioral 
model of health services use functioned as the theoretical model for this study. The 
independent variable was patient travel distance, controlling for established measures of 
risk, including ISS Stage and Gene Expression Profiling based risk stratification. A Cox 
proportional hazard model was used to analyze time to progression and/or death outcome. 
Analysis revealed that patients who lived <120 miles from the site of care were 1.73 
times more likely to experience cancer progression or death than those who lived ≥ 121 
miles. When controlling for ISS Stage and GEP risk, participants who lived <120 miles 
from the site of care were 1.67 times more likely to experience cancer progression or 
death than those who lived ≥ 121 miles. Participants aged ≥ 65 years who lived <120 
miles were 1.88 times more likely to experience cancer progression and 1.75 times more 
likely to die than those who lived ≥ 121 miles. Statistically significant results (p = <.05) 
were obtained for all PFS and OS outcomes with the exception of gender. This study 
promotes social change by improving the care of patients through science-based 
communications with healthcare providers and policy makers. Results from this trial may 
be readily applied to other more common hematologic malignancies.   
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Chapter 1: Introduction to the Study  
Introduction 
Multiple Myeloma (MM) is a hematologic malignancy of plasma cells that is 
characterized by bone marrow failure, anemia, destruction of skeletal bone, renal 
dysfunction, and impaired immune response (Agarwal & Ghobrial, 2013; Mahindra et al., 
2012; Rajkumar, 2011). Despite advances with modern therapy, including autologous 
hematopoietic stem cell transplantation (ASCT), MM has traditionally been characterized 
as an incurable disease (Bianchi, Richardson, & Anderson, 2014; Landgren et al., 2014). 
However, this view has been challenged by investigators citing the long-term outcomes 
of 1,202 patients on Total Therapy protocols (Barlogie et al., 2014) and other published 
evidence indicating that a cure is possible for select groups of patients (Hajek, 2013; San-
Miguel & Mateos, 2011). Cure of MM is functionally defined as no evidence of disease 
by any detection method 10 years after therapy cessation.  
In 2011, the reported median overall survival (OS) for those with newly 
diagnosed symptomatic MM (NDxMM) was reported as 4.4–7.1 years (de Weers et al., 
2011). Significant progress in the treatment of MM in recent years has markedly 
improved both progression-free survival (PFS) and OS (Morgan & van Rhee, 2014), with 
a portion of patients having been cured of their disease. This favorable outcome is limited 
in scope, however. For the majority of MM patients, the disease course is characterized 
by an initial response to therapy, tumor resistance to therapy marked by tumor 
progression, tumor relapse, and death (Mahindra et al., 2012). 
2 
 
This chapter presents the background of MM and discuss both progress and 
challenges confronting public health and medical professionals who are responsible for 
the care of patients with the disease. MM is a late clinical manifestation resulting from 
malignant transformation of plasma cells that inappropriately proliferate and accumulate 
in the bone marrow. Defective and malignant plasma cells found in the bone marrow and 
rarely in extramedullary anatomical sites (Usmani et al., 2012) that produce abnormal 
amounts of monoclonal protein (M-protein), which can damage vital organs 
(Sigurdardottir et al., 2015). At the time of this study, there was broad agreement that 
only symptomatic MM which meets appropriate clinical and laboratory criteria requires 
systematic treatment (Mikhael et al., 2013; Palumbo & Anderson, 2011). This consensus 
in the clinical literature is reflected in the National Comprehensive Cancer Network 
(NCCN) treatment guidelines (Anderson et al., 2014). 
There is not a single, unifying treatment schema that has been demonstrated as 
appropriate for all persons with multiple myeloma. The NCCN is an alliance of 25 cancer 
centers in the United States that produces guidelines for diagnosis and therapy based on 
peer-reviewed evidence and input from experts in the fields of hematology and oncology. 
The NCCN and other groups, including individual physicians, make choices for 
systematic therapy for MM based on clinical evidence, their preferenced, logistical 
considerations, and patient choice. There are well-known barriers to care for those with 
cancer, including socioeconomic status, physical performance status, lack of appropriate 
clinical trials, and geographic location (Chambers & Hyde, 2015). The distance patients 
must travel from their home to their site of care has been identified as a factor which may 
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influence treatment decisions and outcome (Huang, Dignan, Han, & Johnson, 2009; 
Lenhard, Enterline, Crowley, & Ho, 1987; Lipe, Lansigan, Gui, & Meehan, 2012; 
Meilleur et al., 2013; Tariman, Doorenbos, Schepp, Becker, & Berry, 2014). 
There are many appropriate therapeutic regimens available to treat symptomatic 
MM. Treatment regimens for MM may be broadly classified as those intended for 
patients who are candidates for ASCT and those for patients who are not candidates for 
ASCT (Mikhael et al., 2013). Multidrug combinations are routinely used for initial or 
“induction” therapy in NDxMM. Current guidelines and practice patterns routinely 
include between two and three drugs, with some centers utilizing up to seven anti-MM 
drugs for induction therapy (Anderson et al., 2014; Bianchi et al., 2014; Mikhael et al., 
2013; Rajkumar, 2011). This study investigated the impact of patient distance traveled to 
MM care sites, which was not considered in previous research on any disease-specific 
staging or prognostic schema despite evidence suggesting that distance impacts patient 
outcome. This study specifically investigated the impact of patient distance from the site 
of care on survival outcomes using a group of 480 clinical trial participants. Andersen’s 
behavioral model of health services use functioned as the theoretical model for this study. 
Background of the Problem 
Advances in treatment over time have significantly changed the OS for patients 
with MM. The median OS for patients with MM was 17 months prior to the introduction 
of melphalan, an alkylator type of anti-neoplastic drug (National Cancer Institute, 2015b) 
used in combination with the corticosteroid prednisolone (M+P; Alexanian et al., 1972). 
Combination therapy with M+P resulted in an improvement in OS ranging between 19 
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and 39 months (Gregory, Richards, & Malpas, 1992). Thereafter, little progress was 
noted until the introduction of both thalidomide (Thalomid) and bortezomib (Velcade) as 
investigational agents in the late 1990s (R. A. Kyle & Rajkumar, 2014).  
Thalidomide is the first of the immunomodulatory (IMiD) class of drugs and 
bortezomib is the first of the proteasome inhibitor class of medications. These classes of 
medications are commonly referred to as novel therapy in the MM literature (Kumar et 
al., 2008). The introduction of thalidomide and bortezomib in the treatment of both 
NDxMM and relapsed/refractory MM has resulted in significantly improved PFS and OS. 
Kumar (2008) reported a 50% improvement in OS for those diagnosed with MM in the 
years 2001-2006, owing to the use of novel therapy when compared to historic controls.  
Therapy for MM typically involves combination classical chemotherapy with the 
inclusion of one or more novel therapies, independent of the eligibility for the patient to 
undergo future ASCT (Anderson, 2014). Classical chemotherapy agents used in induction 
therapy for MM include doxorubicin (Adriamycin), liposomal doxorubicin (Doxil), 
cisplatin (Platinol), melphalan (Alkeran), etoposide (VePesid), cyclophosphamide 
(Cytoxan), and vincristine (Vincar) (Anderson, 2014). These agents are used in treatment 
regimens consisting of single agents, multi-agents, and in combination with 
corticosteroids (prednisolone, dexamethasone) and/or novel therapies such as thalidomide 
(Thalidomide), lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib 
(Velcade) or carfilzomib (Kyprolis), or other approved and investigational agents 
(Barlogie et al., 2014; Berenson et al., 2014; Mikhael et al., 2013; Rajkumar et al., 2010; 
Stewart, 2012). The use of novel agents in combination with one another but without 
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classic chemotherapy is now an NCCN-approved strategy for therapeutic intervention 
(Anderson et al., 2014). 
Combination therapy utilizing multiple classes of medications has improved both 
PFS and OS for MM, but comes at the expense of significant toxicities and disruptions to 
activities of daily living (Anderson, 2014; Tariman et al., 2014). A hallmark feature of 
multiple myeloma is bone pain associated with lytic bone lesions and impending or 
current vertebral, rib, or long bone fractures (Jethava, Pena, Yoon, Stein, & Zangari, 
2015). Very little qualitative data regarding the impact of therapy and the disease process 
on the quality of life for those undergoing anti-MM therapy were available at the time of 
this study (Baz et al., 2015). Known consequences of untreated disease include fatigue, 
anemia, infection, neuropathy, bleeding, renal dysfunction, hazy vision, headaches, 
hyperviscosity of the blood leading to blood clot formation, decreased performance 
status, and early death (Durie, 2012; Gundrum & Neuner, 2013). Adverse events 
associated with anti-MM therapeutics vary by drug, dose intensity, and drug combination. 
Significant adverse events associated with classical chemotherapy, corticosteroids, and 
novel agents include anemia, bone marrow suppression (anemia, thrombocytopenia, 
neutropenia), constipation, somnolence, cardiac failure, edema, rash, neuropathy, and 
deep vein thrombosis/pulmonary embolism (DVT/PE; Mateos, 2010). 
There are multiple models for staging and prognostication of MM. These models 
include:  
• the European Group for Blood and Marrow Transplantation (EBMT) criteria 
(Bladé et al., 1998)(Bladé et al., 1998; Appendix A),  
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• Durie-Salmon Staging System (Durie & Salmon, 1975; Appendix B),  
• the International Staging System (ISS; Greipp et al., 2005; Appendix C),  
• the International Myeloma Working Group (IMWG) CRAB criteria (Rajkumar et 
al., 2014; Appendix D),  
• Gene Expression Profiling (GEP70; Shaughnessy et al., 2007), and seperately 
• the Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) 
Consensus Guidelines 2013 (Mikhael et al., 2013), which utilize a broad array of 
clinical features, laboratory, imaging, cytogenetic, and genetic information to 
guide therapy and prognosticate for survival.  
Orally administered treatment regimens, including thalidomide-dexamethasone, 
lenalidomide-dexamethasone, pomalidomide-dexamethasone, or melphalan-prednisone, 
are often chosen by physicians and patients as they do not require patients to undergo 
central line placement or make frequent visits to the infusion clinic. At the time of this 
study, no quantitatively designed disease staging, prognostication, disease response 
systems, or clinical care guidelines considered the potential impact of the distance a 
patient must travel to the site of cancer care as a variable in therapy. 
Statement of the Problem 
This study was designed to close a gap in literature with regard to the potential 
impact of patient distance traveled in the era of novel therapies, improved autologous 
stem cell transplantation (ASCT) outcomes, and supportive care for those with NDxMM. 
Previous findings on the potential impact of distance traveled on PFS for patients with 
MM are inconsistent (Abou-Jawde et al., 2006; Lenhard et al., 1987; Lipe et al., 2012). 
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Previously published work on this topic revealed a lack of consistent patient populations 
studied, were based on data that were published 25 years ago and therefore did not 
include novel therapies, and contained significant methodological errors (Lenhard et al., 
1987; Ojha et al., 2007). In a retrospective report based on 27,987 patients with NDxMM 
from 1998-2000 derived from the National Cancer Center Data Base, 7.9% survived > 10 
years (Raghavendra, Al-Hamadani, & Go, 2013). Amongst the small fraction of patients 
who survived > 10 years, residence in a metropolitan area, high education level, high 
income, ASCT, and initial treatment at an academic medical center were significantly 
associated with > 10 year survival; however, multivariate analysis demonstrated that the 
geographic location of residence, sex, ethnicity, or household median income were not 
significant factors associated with OS (Raghavendra et al., 2013). Raghavendra et al. 
(2013) concluded that sociodemographic and other significant healthcare disparities exist 
for those who are treated for NDxMM.  
ASCT is not an appropirate or feasible treatment option for a subset of patients 
with NDxMM, including older adults and those with poor performance status (Anderson 
et al., 2014; Palumbo et al., 2011). Investigators from the Dartmouth Hitchcock Medical 
Center, who retrospectively evaluated the impact of multiple prognostic variables, 
including distance from the cancer center for those who did undergo ASCT, concluded 
that increasing distance from the cancer center was associated with improved OS and 
disease free survival (Lipe et al., 2012). Lipe et al. (2012) acknowledged the limitations 
of their analysis, including a selection bias to only include patients who were eligible for 
ASCT and small sample size. Investigators from the Cleveland Clinic Myeloma Research 
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Program also performed a retrospective analysis examining, among other variables, the 
impact of patient distance traveled on clinical outcomes among Black patients with both 
NDxMM and relapsed/refactory MM, concluding that socioeconomic status, race, and 
distance traveled did not affect outcome (Abou-Jawde et al., 2006). A rejoinder to Abou-
Jawde et al. (2006) by Ojha et al. (2007) identified methodlogical flaws including over 
estimation of the impact of serum albumin and β-2 microglobulin, inconsistent patient 
populations studied, and insufficient statistical power, raising serious concerns regarding  
the results of the research.  
This study addressed the gap in the literature utilizing data from The Myeloma 
Institute for Research and Therapy (MIRT) located at the University of Arkansas for 
Medical Sciences (UARK, a.k.a, UAMS) in Little Rock, Arkansas, USA. MIRT is the 
largest dedicated research and treatment center for MM in the world. As an international 
and state reference center for MM, MIRT attracts and treats patients from all over the 
globe (Arkansas Online, 2014; Talk Business and Politics, 2014). Research originating 
from MIRT includes the discovery of thalidomide as an active anti-myeloma drug 
(Singhal et al., 1999), the use of gene expression profiling as a tool to differentiate high 
risk multiple myeloma (HRMM) from low risk multiple myeloma (LRMM) 
(Shaughnessy et al., 2007), and the performance of both single and tandem ASCT on 
outpatients. The Total Therapy approach of applying all therapeutically active 
pharmaceutical drugs and procedures, including ASCT in the treatment of newly 
diagnosed MM has been applied in successive clinical trials at MIRT, originating with 
Total Therapy 1 in 1989 to Total Therapy 6, which is still accruing subjects in late 2015. 
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There is a clear need to identify the potential impact of the distance from a 
patient’s home to MIRT on PFS and OS for those treated at MIRT for NDxMM. At the 
time of this study, MIRT had never formally investigated the potential impact of patient 
distance traveled on PFS and OS. Given the central Arkansas location of MIRT, volume 
of patients with NDxMM treated, the role of MIRT/UARK as a state-operated medical 
facility, and its worldwide referral base, MIRT has the data and capacity to inform the 
community by investigating the potential impact of patient distance traveled on PFS and 
OS for those with NDxMM in a quantitative, retrospective study. Owing to the large 
sample size, uniform treatment, and long term follow up of subjects with NDxMM, the 
TT3 dataset was chosen to inform this study. The TT3 trials were among the first to 
prospectively combine novel therapies with ASCT and consolidation in the newly 
diagnosed setting and are among the most mature trials for long-term follow up in this 
patient population. The TT3 trials evaluated PFS and OS that are measured in days and 
reported as months/years. 
Purpose of the Study 
The purpose of this study was to determine if those patients with NDxMM who 
live within close proximity to MIRT have different PFS or OS outcomes than those who 
live outside of close proximity to MIRT in the TT3 clinical trials. TT3 is one of the first 
prospective clinical trials that combined novel therapy with chemotherapy, followed by 
ASCT and novel drug maintenance therapy in NDxMM patients (see Appendix E and 
Appendix F). The distance of <121 miles from MIRT was chosen to include most of the 
State of Arkansas and UARK-affiliated regional health centers (formerly known as 
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AHECs), and because this distance corresponds to MIRT being reasonably reachable 
with approximately 2 hours of travel time by automobile.  
This study was designed to produce findings that will positively influence the 
delivery of MM care and other more common hematologic malignancies such as 
leukemia and lymphoma. It specifically tested whether or not proximity to the site of care 
was associated with longer PFS. Findings from translational and clinical research in MM 
have been applied to more commonly encountered hematologic malignancies, including 
leukemia and lymphoma. For example, the novel therapies lenalidomide and bortezomib, 
first studied in MDS and MM, are now routinely utilized in the management of mantle 
cell lymphoma and are FDA approved for use in this disease. Findings from studies 
utilizing ASCT for MM are commonly applied to those who are undergoing the 
procedure for diffuse large B cell lymphoma. 
Many U.S. insurance companies do not provide financial benefits to allow a 
patient and/or family to travel to a distant site for cancer care.  Hospital admission may 
be the only mechanism to provide room and boarding for a patient with cancer (Alonso-
Zaldivar, 2014). High socioeconomic status (SES) has been associated with better 
outcomes among a variety of health conditions, including multiple myeloma (Paul, Hall, 
Carey, Cameron, & Clinton-McHarg, 2013; Raghavendra et al., 2013). This suggests that 
high SES may enable a person with NDxMM to travel to a reference center for the 
disease and have the ability to temporarily relocate to the area to allow for protocol 
enrollment or off-protocol therapy.  This ability to travel and temporarily relocate for care 
11 
 
is not covered by many insurance companies and those with limited financial resources 
are less likely to be able to temporarily relocate to the site of care for their disease. 
Research Questions and Hypotheses 
The primary objective of this study was to determine if there qs a difference in 
PFS or OS for those with NDxMM who live <121 miles from MIRT compared to those 
who live ≥ 121 miles from MIRT in TT3. The hypothesis suggests there may be a 
difference in PFS and OS due to logistical or patient care challenges in both planned and 
nonscheduled visits (owing to complications attributable to the disease or treatment 
related toxicities). In many rural practice settings, the specialized medical expertise 
required to treat MM, along with medical complications of the disease or its treatment, 
may not be readily available. 
Several research questions were used to investigate the study hypothesis. Key 
terms used in the research questions were: 
• GEP70 – Gene expression profiling of 70 genes related to MM, to define the risk 
classification of multiple myeloma as HRMM or LRMM (Shaughnessy et al., 
2007; van Laar et al., 2014). GEP70 is a molecular diagnostic. 
• Close proximity to MIRT – Distance from a patient’s zip code of residence to 
MIRT is < 121 miles. 
• Outside close proximity to MIRT –- Distance from a patient’s zip code of 
residence to MIRT is ≥ 121 miles. 
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Research Question 0 
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS 
in TT3? 
Null hypothesis (H00): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT. 
Alternative Hypothesis (HA0): There is a statistically significant difference to PFS 
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70-
defined risk and ISS Stage.  
Research Question 1 
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS 
in TT3, when controlling for GEP70-defined risk and ISS Stage? 
Null hypothesis (H01): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk 
and ISS Stage. 
Alternative Hypothesis (HA1): There is a statistically significant difference to PFS 
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined 
risk and ISS Stage.  
Research Question 2 
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to 
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS 
Stage? 
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Null hypothesis (H02): There is no statistically significant difference in PFS or OS 
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for 
GEP70-defined risk and ISS Stage. 
Alternative Hypothesis (HA2): There is a statistically significant difference in PFS 
or OS based on a patient age ≥ 65 years and close proximity to MIRT after controlling for 
GEP70-defined risk and ISS Stage. 
Research Question 3 
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT 
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage? 
Null hypothesis (H03): There is no statistically significant difference on PFS or OS 
based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. 
Alternative Hypothesis (HA3): There is a statistically significant difference on PFS 
or OS based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. 
Theoretical Basis of the Study 
The theoretical framework used for this study was Andersen’s behavioral model 
of health services utilization (BMH). BMH was originally created in the 1960s to explain 
why families use healthcare services, but has been updated to reflect individual choices in 
healthcare services consumption (Andersen, 1995). The behavioral model of health 
services utilization posits that there are three critical factors (predisposing factors, 
enabling factors, and need factors) that influence an individual’s use of health care 
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services (Anderson, 1995). Andersen’s model has been subsequently adapted for use in a 
variety of medical and social research applications, including cancer screening (Rahman, 
Dignan, & Shelton, 2005).  
Anderson (1995) described three sets of factors: 
• predisposing factors consisting of demographic descriptors of a population, such 
as age and ethnicity;  
• enabling factors that allow a person to access health services, including financial 
resources, health insurance, and geographic location; and  
• need factors consisting of motivating reasons that a person would seek to access 
healthcare such as health screening, acute illness, or trauma (Anderson, 1995). 
MM is the late manifestation of the accumulation of malignant plasma cells in the bone 
marrow or extramedullary anatomical sites, which may cause anemia, bone pain, fracture, 
or immune suppression leading to infection (Colson, 2015). The application of 
Andersen’s model to NDxMM and this study allows for predisposing factors associated 
with MM, enabling factors, and need factors to be used to explain any potential 
differences in patient outcome. 
In this study, the three essential factors of the BMH model were utilized and 
evaluated as either dependent or independent variables. This study analyzed secondary 
data obtained from a prospective clinical trial; the factors that prompted to present to 
MIRT (opposed to another cancer center) for therapy are not were recorded in the 
original dataset. Table 1 shows the alignment of the three essential BMH factors with 
study variables.  
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Table 1    
    
BMH Constructs and Relationship to Study Variables 
    
BMH Construct Description Database Study variable 
Age Predisposing factor Age at enrollment Independent 
Ethnicity Predisposing factor Not reported N/A 
SES Status Enabling Not collected Potential Confounder 
Geographic location Enabling <121 miles, or >= 121 miles Independent 
NDxMM diagnosis Need ISS Stage Independent 
 
Nature of the Study 
The study was a quantitative, retrospectively based secondary analysis of data 
obtained from MIRT’s TT3a (Barlogie, 2003) and TT3b protocols (Barlogie, 2006) that 
enrolled patients with NDxMM. The study investigated PFS and OS outcomes where 
PFS is measured as the time from study enrollment to disease progression/relapse or 
death from any cause, and OS is measured as the time from study enrollment to death 
from any cause, according to the EBMT criteria (Bladé et al., 1998). The dependent 
variables are PFS and OS. Independent variables include close proximity to MIRT based 
on patient zip code at TT3 study registration, gender, age ≥ 65 years, GEP70-defined risk 
status (HRMM or LRMM), and ISS stage. The data to inform this study were collected 
from prospective clinical trials for those with NDxMM conducted at MIRT. The data 
collected for clinical decision-making and research purposes originated from the TT3 
clinical trials, which were approved by the Institutional Review Board (IRB) at UARK 
and by appropriate U.S. regulatory agencies, including the U.S. Food and Drug 
Administration. The secondary dataset that was analyzed in the study was void of 
personally identifiable, protected health information. The Institutional Review Board 
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(IRB) at both UARK and Walden University approved this study. All persons meeting 
eligibility criteria who were enrolled on TT3 will be evaluated. The National Cancer 
Institute (NCI) (grant CA 55813) supported the TT3 trials. Bart Barlogie, M.D., Ph.D., 
was the principal investigator (PI) for both trials. In the TT3a protocol, 303 patients were 
enrolled, with an additional 177 enrolled on the extension trial TT3b. In total, data from 
all 480 patients enrolled to both trials was evaluated in a survival analysis defined by PFS 
and OS.  
The Cox proportional hazard (PH) model was utilized to analyze the data for time 
to event for PFS and OS outcomes. Covariates were chosen and are founded in the peer-
reviewed MM literature. Additional Cox PH analysis was performed to determine if 
distance impacts PFS or OS while controlling for GEP70-defined risk and ISS stage. A 
result is considered statistically significant if a p value is < .05. 
In the TT3 protocols, patients must have met the CRAB criteria (Calcium 
elevation, Renal insufficiency, Anemia, and Bone lesions), indicating that systemic 
treatment for MM was medically indicated (Kyle et al., 2003). MM was staged according 
to the ISS criteria (Greipp et al., 2005). Disease response and progression are defined by 
the EBMT criteria (Bladé et al., 1998). Retrospective review was chosen for this study 
based on three primary considerations. First, data and outcomes are available for patients 
treated on two prospective clinical trials (TT3a/b), the results of which have been 
published in the peer-reviewed literature (Barlogie et al., 2007; Nair et al., 2010). Second, 
if the data and analysis indicate that those who live in close proximity to MIRT have 
longer PFS and/or OS, with other factors being controlled for, this provides rationale to 
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implement policy change. Third, the time required to prospectively collect these data and 
analyze for the primary objective of the study puts patients at undue risk of harm, if the 
null hypothesis cannot be rejected. 
Definition of Key Terms 
The following list provides definitions of key terms and variables, which are used 
to describe multiple myeloma, and research terminology. A list of abbreviations is 
located in Appendix G.  
Adverse event (AE): Any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporarily associated with the use of a medical 
treatment or procedure that may or may not be considered related to the medical 
treatment or procedure (Cancer Therapy Evaluation Program, 2003, p. 1). In the TT3 
protocols, all adverse events are graded according to the NCI Common Terminology for 
Adverse Events, Version 3.0 (Cancer Therapy Evaluation Program, 2003). 
European Group for Blood and Marrow Transplantation (EBMT): A European 
cooperative group focusing on research related to bone marrow transplantation.  
GEP70: Gene expression profiling of 70 genes related to MM, utilizing purified 
plasma cells (CD138+) and the Affymetrix U133Plus2.0 gene micro array, (Shaughnessy 
et al., 2007). 
GEP70 Low Risk MM: Low-risk MM according to the GEP70 model, with a 77% 
probability of 5-year event-free survival (Shaughnessy et al., 2007; van Laar et al., 2014).  
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GEP70 High Risk MM: High-risk multiple myeloma according to the GEP70 
model, with a 34% probability of 5-year event-free survival (Shaughnessy et al., 2007; 
van Laar et al., 2014). 
International Staging System (ISS): A validated schema to classify and stratify 
patients diagnosed with MM risk that is used in research and standard practice (Greipp et 
al., 2005). 
Monoclonal Gammopathy of Undetermined Significance (MGUS): The presence 
of an M-protein <30g/L, bone marrow clonal plasma cells <10%, no end organ damage, 
and no evidence of B-cell lymphoma or other disease known to produce an M-protein. A 
pre-neoplastic condition (Surveillance, Epidemiology, and End Results Program (SEER), 
2015). 
Myeloma Institute for Research and Therapy (MIRT): A center for clinical care 
and research that is located at the University of Arkansas for Medical Sciences. 
Multiple Myeloma: A hematologic malignancy of plasma cells that produce 
abnormal amounts of immunoglobulin or immunoglobulin protein fragments, which 
meets the CRAB clinical criteria (Kyle et al., 2003; see Appendix D). 
Overall Survival: Time from study enrollment to death from any cause (Barlogie, 
2003). 
Progression Free Survival: Time from study enrollment to disease progression or 
death from any cause (Barlogie, 2003). 
Tandem Transplant: Two planned autologous stem cell transplants during initial 
therapy. 
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Total Therapy 3a/b (TT3): Prospective clinical trials of 480 newly diagnosed 
persons with MM (Barlogie, 2003, 2006). 
University of Arkansas for Medical Sciences (UARK): The University of Arkansas 
for Medical Sciences located in Little Rock, Arkansas. 
Assumptions, Limitations, and Scope of Study 
Four major assumptions were made for this research study: (a) the data from TT3 
were nonbiased, accurate and were recorded accurately in the multiple myeloma database 
(MMDB); (b) the patients who were enrolled and evaluated on TT3 provided written 
informed consent, met the eligibility criteria as established by the respective protocols, 
and were compliant with the treatments and procedures that informed the protocols; (c) 
patients that were enrolled to the TT3 protocols were representative of NDxMM patients 
who were treated at an academic medical center during the years the respective studies 
were actively accruing; and (d) the data evaluated in the study would adequately answer 
the research questions in the study. 
Assumptions 
The Total Therapy 3a/b protocols were subject to UARK IRB and FDA oversight, 
and were audited for protocol compliance, disease progression, and death attribution by 
an independent, outside group of study auditors, led by Raymond Weiss. It was assumed 
that the data analyzed in this study are without bias and reliable as the data were obtained 
from research and clinical records. Known sources of bias which may be present in this 
study include data from a single center (Bellomo, Warrillow, & Reade, 2009) and the use 
of PFS as an endpoint (Booth & Eisenhauer, 2012; Korn & Crowley, 2013). 
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Limitations 
A known limitation of this study was the use of secondary data for analysis. 
Although data obtained from the TT3 protocols were collected specifically to address 
PFS and OS in the study population, the investigational variable of distance was not 
considered at the time of data collection. The TT3 protocols were not randomized trials. 
The data collected and recorded were not originally intended to collect geographic data, 
thus if a subject changed geographic location during the study period, this information 
would not have been collected and could therefore confound the planned analysis.  
The TT3 protocols were designed and implemented by a group of hematologists 
who are experts in the diagnosis and treatment of MM. MM is a relatively rare condition, 
accounting for approximately 1% of adult neoplastic disease (Palumbo & Anderson, 
2011). The expertise and resources available to treat MM may not be available in other 
treatment settings, independent of geographic location or socioeconomic status of 
patients. Socioeconomic status of study participants was not evaluated as a part of the 
TT3 protocols and will not be analyzed in this research. Factors that influenced an 
individual subject to participate in the TT3 trials are unknown; however, a diagnosis of 
MM was confirmed per TT3 protocol.  
Disparities in outcomes of patients with cancer, including MM, based on multiple 
factors including socioeconomic status, race, and geographic location are well described 
in the literature (Chambers & Hyde, 2015; Landgren et al., 2014; Waxman et al., 2010). 
As a state-operated medical center, UARK is duty bound to treat patients without regard 
to their ability to pay or any demographic descriptor. The pre-malignant condition of 
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MGUS is a known risk factor for the development of MM; however, with the exceptions 
of avoiding exposure to pesticides, avoiding obesity, and potentially a trial of a 
therapeutic agent to treat MGUS if diagnosed, there are no known health related 
behaviors or socioeconomic status which may prevent MM (Landgren et al., 2014; 
Rajkumar, 2011). Lastly, when the TT3 protocol was initiated, the EBMT (Bladé et al., 
1998) criteria were used to categorize disease response; these criteria have subsequently 
been replaced by the IMWG criteria in research and clinical practice (Rajkumar et al., 
2014).  
Scope of Study 
This study sought to address a gap in the peer-reviewed literature with regard to 
the potential impact of patient distance traveled on PFS for those with NDxMM. MM 
therapy has significantly improved outcomes in the past decade (Barlogie et al., 2014; 
Morgan & van Rhee, 2014). Although geographic location and patient distance traveled 
are factors for consideration in clinical care and clinical trial participation (Tariman et al., 
2014), the role of distance is not considered in any prognostication, treatment, or disease 
staging system. MIRT is a world recognized leader in the research and treatment of MM 
and is one of the most commonly cited references in the peer-reviewed literature specific 
to MM (J.-P. Andersen et al., 2015). TT3 study results have been published in the peer-
reviewed literature and have influenced the treatment of MM patients worldwide (J.-P. 
Andersen et al., 2015; Anderson, 2014). This study did not incorporate findings from a 
recently published manuscript from investigators at MIRT who demonstrated that 
CYR61/CCN1 overexpression in the bone marrow microenvironment was associated with 
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superior survival and reduced bone disease in patients treated on the TT3 protocol 
(Johnson et al., 2014). The data to inform the report from Johnson and associates (2014) 
was obtained retrospectively, have not been validated in other data sets, and represent 
experimental findings that are not likely to be reproducible in other research or clinical 
settings. 
The results from this study may influence treatment and clinical trial decision-
making based on patient distance from MIRT in the future, and these findings may also 
be applicable to other medical centers that treat hematologic malignancies. If distance is 
found to be a significant variable which impacts outcome, special procedures and 
protocols, such as the Very Immunocompromised Patient (VIP) protocol (Schindler, 
2015), could be considered for implementation at MIRT. 
Potential for Positive Social Change 
MM is generally regarded as an incurable malignancy impacting older persons 
(Libby et al., 2014; Rajkumar, 2011) that necessitates chemotherapeutic treatment to 
delay progression of the disease. Despite significant progress in the treatment of MM, 
measured by increased PFS and OS in recent years, most patients relapse from their 
disease (Ferrero et al., 2015; Heuck et al., 2014). Improvement in PFS and OS has also 
resulted in peripheral neuropathy, cardiac events, and financial toxicity (Boland et al., 
2013; Colson, 2015; Khera, 2014). The distance from a patient’s home to the site of 
therapy for MM is not considered in established prognostic or therapeutic designs, 
despite the potential of distance to impact PFS or OS. This study utilized Andersen’s 
theoretical framework of the BMH (Andersen, 1995) and quantitative analysis of two 
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large clinical trials TT3a/b (Barlogie, 2003, 2006) to determine if living in close 
proximity to MIRT has an impact on PFS or OS. The peer-reviewed literature is limited 
and contradictory on the potential of patient distance traveled to impact PFS and OS for 
those undergoing treatment for NDxMM in the era of novel therapy. The clinical 
protocols TT3a/b prospectively investigated PFS and OS in NDxMM at MIRT and 
represent one of the largest datasets utilizing novel therapies, ASCT, and maintenance 
therapy in the first line setting. The data derived from TT3 will serve to inform the 
research questions raised in this research study. 
Significance of the Study 
MIRT is one of the few centers in the world where GEP data and clinical 
outcomes are collected for nearly all patients on a longitudinal basis, thus presenting the 
opportunity to conduct the largest trial ever reported investigating the potential impact of 
patient distance traveled in NDxMM in the era of novel therapy in combination with 
planned ASCT, followed by multi-agent maintenance therapy. This study is unique as 
MIRT has the largest database of clinical outcomes and genetic material from CD138+ 
(multiple myeloma tumor cells) in the world that has undergone GEP. Patients with 
NDxMM, independent of risk stratification, face significant health challenges due to drug 
toxicity, infection, tumor lysis, renal complications, skeletal fractures, and other disease 
related sequela. Access to appropriate and specialized medical care for the treatment of 
these morbidities is critical. The distance from a patient’s home to the site of care may be 
a significant variable on clinical outcomes. 
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Summary and Transition 
Treatment of MM is reserved for those persons who have symptomatic MM 
meeting the CRAB diagnostic criteria Therapeutic regimens for MM have improved OS 
and PFS in the preceding decade (Barlogie et al., 2014; Kumar et al., 2008; Nair et al., 
2010); however, treatment for MM often results in decreased quality of life, frequent 
clinic visits, and toxicities (Baz et al., 2015; Boland et al., 2013; Paul et al., 2013). 
Although there have been multiple peer-reviewed articles which address the question of 
patient distance traveled and the potential impact on PFS and OS, none of the peer-
reviewed and expert-generated guidelines for MM disease prognostication and treatment 
address the variable of patient distance traveled to the site of care.  
This study sought to address a gap in the literature through an analysis of 
secondary data obtained from the TT3 clinical trials for persons with NDxMM. The TT3 
clinical trial dataset contained all necessary information to investigate the potential 
impact of patient distance travelled on PFS and OS outcome. The use of a dataset that 
contained genetic and classic disease staging information allowed for these known 
influencers on disease outcome to be controlled for in the analysis.  
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Chapter 2: Literature Review 
Introduction and Background 
The purpose of this quantitative study of 480 clinical trail participants was to 
investigate the impact of patient distance from the site of care on survival outcomes for 
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. Previous, 
peer-reviewed studies have yielded inconsistent conclusions regarding the issue of patient 
distance traveled to the site of care for multiple myeloma (MM) treatment. This chapter 
presents a critical review of the peer-reviewed literature to provide background on the 
pathophysiology of MM and its treatment, as well as a review of published data regarding 
the impact of distance on outcomes, and expected outcomes after therapy. The chapter 
begins with a review of the search strategy for contemporary literature review. The 
functional role of a healthy plasma cell in immunity, epidemiology, pathophysiology, and 
other essential elements to characterize MGUS and MM, including disease staging, risk 
stratification, and common treatments are presented.  
Literature Search Strategy 
The primary research strategy utilized the electronic review of publically 
available databases, including PubMed, EBSCO, Cochrane Collection, Web of Science, 
relevant English literature, peer-reviewed journals, and medical textbooks. It also 
included a review of proceedings from the respective annual meetings of the American 
Society of Clinical Oncology (ASCO) and the American Society for Hematology (ASH), 
because these organizations are among the most reputable sources of information to 
inform cancer research and treatment. The search was performed using keyword searches 
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on the Google Scholar search engine, relating to the purpose and research questions of 
the study, including multiple myeloma, myeloma, newly diagnosed, MM, MGUS, 
monoclonal gammopathy of undetermined significance, plasma cell dyscrasia, plasma 
cell leukemia, health belief model, behavioral model of health services, distance, 
epidemiology, geography, site of care, gene expression profiling, paraproteinemias, risk 
stratification, treatment, Total Therapy, autologous stem cell transplant, ASCT, and 
cytogenetics as singular terms and in key word combinations with the Boolean operators 
“AND,” “OR,” “NOT.” The majority of the data used in this literature review was 
obtained from peer-reviewed literature published from 2011 to 2015, and was focused on 
clinical outcomes and human data. Peer-reviewed literature older than 2011 was used 
when more recent data were limited or when the resources were essential reports in the 
history, diagnosis and treatment of multiple myeloma which were published prior to 
2011. 
Theoretical Framework 
The theoretical framework used for this study was a modified version of 
Andersen’s behavioral model of health services utilization (BMH; Anderson, 1995).  
BMH was originally developed in the 1960s to explain why families use healthcare 
services, and has been subsequently updated and modified by its original author. 
Progressive phases of the model have been published and purport to better inform 
individual healthcare decision making and its influences on patient outcomes. Phase four 
of the Andersen model was chosen to inform this study as it has been widely utilized in 
health related behavior research (Anderson, 1995). The behavioral model of health 
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services utilization describes three critical factors that influence an individual’s use of 
health care services: 
• predisposing factors,  
• enabling factors, and need factors (Anderson, 1995).  
Figure 1 presents Phase 4 of Andersen’s model. 
 
 
Figure 1. Phase 4 of Andersen’s BMH model put for by Anderson. Andersen,  R.M. 
(1995). Revisiting the behavioral model and access to medical care: Does it matter? 
Journal of Health and Social Behavior, 36, 1-10.  Copyright 1996 Journal of Health & 
Social Behavior, property of the American Sociological Association. Reprinted with 
permission. (See Appendix N). 
 
One predisposing factor of an individual to access healthcare services is age. The 
data to inform this study originated from two prospective clinical trials that, by protocol 
design, only allowed persons aged 18 years or older to participate. MM is associated with 
increasing age and is most commonly diagnosed in the seventh decade of life (National 
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Cancer Institute, 2015c). Participant age is noted by Andersen to impact health care 
decision making as influenced by social interaction and networks and culture (Andersen, 
1995). Age over 65 years was an independent variable in this study.  
Ethnicity is another predisposing factor in Andersen’s BMH model. Applied to 
this study, ethnicity information was collected but not analyzed, as the sample population 
was not large enough to allow for stratification based on ethnicity. Ethnicity and race are 
known to impact the incidence of MM at the population level. This scope of this study 
and sample population did not allow ethnicity as a variable; however, additional 
information regarding race and ethnicity is provided in this chapter. Andersen posits that 
the choice to access health care services is multifactorial and is influenced by individual 
beliefs and external factors that have feedback mechanisms. Andersen (1995) suggested 
that genetic information could be considered as a potential predisposing characteristic; 
the development of MM is associated with heritability, however the use of genetic 
screening is not currently in routine clinical practice. Genetic information was obtained 
from CD138+ cells and analyzed in this study but germline mutations were not analyzed. 
Andersen (1995) described enabling factors such as an individual’s financial 
resources, health insurance, and geographic location as elements that enable them to 
access healthcare services. SES, geographic location, and the existence of a health care 
provider undoubtedly influence access to care (Andersen, 1995, p. 3). Enabling factors 
such as health insurance status have broad influence on health care outcomes and health 
policy is beyond the scope of this study. As a theoretical model, the BMH acknowledges 
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that culture, biologic necessity, and access to care all influence health care services 
utilization (Andersen, 1995).  
Geographic location is an enabling factor in the BMH model and as applied to this 
study is a dependent variable. MM is a rare disease in the general population and is 
typically treated, within the confines of a U.S. medical system model by an oncologist or 
hematologist. Many rural communities do not have a local oncologist/hematologist, 
which is a limiting factor according to the BMH model. The current study utilizes 
distance, measured in miles, from MIRT as a potential influencer of PFS and OS 
outcome. The medical expertise and resources to diagnose and treat MM may not be 
present in all communities, thus distance may be an enabling factor to access care and 
influence treatment. Andersen suggests that burdens to access health care, such as 
distance or living in a rural community without ready access to the resources required to 
treat a disease may influence an individual’s decision to seek care for their condition 
(Andersen, 1995). The current study did not examine the factors that influenced an 
individual’s choice to seek care at MIRT; rather it used geographic distance from MIRT 
as a surrogate for ready access to specialized medical care.  
Andersen (1995) suggests that realized access to care is the actual use of services 
and for the purposes of this study; all participants had access to care and were able to 
meet eligibility criteria for enrollment on a Phase II clinical trial. The ability to access a 
specialized tertiary care facility is a complex issue such that a wide spectrum of SES is 
represented. SES is an acknowledged influencer of health status, health service utilization 
and a potential confounder in this study. 
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The need to seek medical care was described by Andersen (1995) as a variable 
that is subject to interpretation by an individual and their perceptions of health or 
financial factors. Perceptions of need to seek treatment for asymptomatic conditions such 
as hypertension are likely different from high symptomatic conditions, such as MM. MM 
is clinically notable for variety of clinical symptoms including anemia, bone pain and 
fracture (Colson, 2015). MM is an uncommon malignancy and it is unlikely that the 
general public would not have any knowledge of the need to be treated for MM unless 
and until the disease was detected or there was a family history of MM. The need to seek 
care for MM was not directly assessed in this study; however, the disease burden as 
measured by the ISS was assessed and may be used as a proxy for need, such that life 
expectancy is correlated with ISS stage. A limitation of this construct in the current 
setting is the protocol driven study procedures and therapeutic regimen; the TT3 trials are 
aggressive trials aimed at disease cure not palliation or pain control. As applied to BMH 
model, this study does not address the dimension of need for those who are unfit, 
unwilling, or unable to undergo aggressive therapy for NDxMM. 
Role of Normal Plasma Cells in Human Immunity 
Plasma cells (PCs) are terminally differentiated B-cells that produce 
immunoglobulins (Igs), which are utilized by the human immune system to identify and 
neutralize pathogenic organisms including viruses, bacteria and cancer cells via 
recognition of antigens (Pellat-Deceunynck & Defrance, 2015; Tai & Anderson, 2011). 
Five major isotypes of Igs have been identified in humans: IgA, IgD, IgE, IgG, and IgM 
(Brioli et al., 2014). The five major Igs are known as heavy chain isotypes, with two 
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accompanying kappa (κ) or lambda (λ) light chains (Munshi, Longo, & Anderson, 2012). 
In MM, excess proteins derived from clonal plasma cells are secreted into the serum and 
urine, which is known as an “M spike.” When excess proteins caused by clonal plasma 
cells are detected only in the urine, this is known as Bence-Jones protein. MM may be 
caused by any of the major heavy or light chain proteins. The κ/λ ratio is used clinically 
to monitor the disease/tumor burden (Anderson, 2014; Brioli et al., 2014). In the 
normally functioning immune system, Igs form the basis of circulating antibodies that are 
critical to the humoral immune response. Each combination of heavy chains and light 
chains produces a specific immunoglobulin molecule (protein). 
Disease Definitions 
MGUS is defined by the IMWG as the presence of an M-protein < 30 g/L in 
serum, bone marrow clonal PCs < 10% and low level of PC infiltration in a trephine 
biopsy, no evidence of other B-cell proliferative disorders, and no organ or tissue 
impairment, including bone lesions (Kyle et al., 2003, p. 752). 
Smoldering MM (SMM) is defined as serum protein (IgG or IgA) ≥ 30 g/L or 
urinary monoclonal protein ≥ 500 mg per 24 hours and/or clonal bone marrow PCs 10%-
60% and the absence of myeloma defining events (Rajkumar et al., 2014, p. 541).  
The revised IMWG diagnostic criteria define (clinical/symptomatic) MM by the 
presence of ≥ 10% clonal PCs in the bone marrow and/or presence of a biopsy-proven 
bony or extramedullary plasmacytoma (Rajkumar et al., 2014) and myeloma defining 
events defined by the CRAB criteria (Kyle et al., 2003). The following biomarkers are 
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also indicative of MM, clonal bone marrow PC ≥ 60%; involved/uninvolved serum free 
light chain ratio § ≥ 100; > 1 focal lesion by MRI (Rajkumar et al., 2014, p. 541). 
Plasma Cells, Monoclonal Proteins, and MGUS 
Plasma cells secrete antibodies into the circulation to assist in normal immune 
function. In MGUS, single plasma cells proliferate (clones) without antigen exposure, 
and produce a single monoclonal (M) protein that may be detectable in urine, serum or 
other tissues (R. Kyle & Rajkumar, 2015). This nonantigen stimulated production of an 
M protein is the manifestation of abnormal plasma cell function. MGUS is characterized 
by the detection of M protein without end-organ damage or other benign or 
hematological conditions (R. Kyle & Rajkumar, 2015). MGUS almost universally 
precedes MM. The rate of “conversion” from MGUS to MM is approximately 1% per 
year (Rajkumar, 2015). 
MGUS is frequently referred to as a single disease state in the literature, although 
there are multiple “classifications” of MGUS based on Ig subtype (Agarwal & Ghobrial, 
2013; Landgren, 2013) and risk of conversion to MM (Gundrum & Neuner, 2013; 
Mateos et al., 2013). In a prospective cancer screening study of more than 77,000 patients 
aged 55-74 years, nearly all of the 71 patients who were diagnosed with MM had a 
preceding MGUS diagnosis (Landgren, Kyle, Pfeiffer, et al., 2009). In this literature 
review and research study, MGUS is defined as a single entity according to the IMWG 
criteria. 
MGUS is typically associated with older age, which may also be associated with 
comorbidities that require more frequent medical care, thus leading to laboratory 
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investigations which revealed MGUS, when it would have gone undiagnosed in patients 
who did not seek frequent medical care (R. Kyle & Rajkumar, 2015). In a large study 
investigating the outcomes of patients with MGUS, it was concluded that patients with 
MM who were aware of a prior MGUS diagnosis had better OS (median 2.8 years) 
compared to those patients who were not previously diagnosed with MGUS (median 2.1 
years), suggesting that MGUS patients who were clinically monitored at regular intervals 
experienced earlier detection of MM (Sigurdardottir et al., 2015). Clinical guidelines 
suggest that patients with MGUS be monitored for disease progression to MM but that no 
treatment for the disease be offered, owing to the low rate of conversion to MM and the 
toxicities associated with treatment (Anderson, 2014; R. Kyle & Rajkumar, 2015; 
Rajkumar et al., 2014). 
Historically, treatment with anti-MM agents directed towards MGUS resulted in 
toxicity with little clinical benefit. One recent study demonstrated that the anti-MM 
therapy combination of lenalidomide + dexamethasone, for those with high risk MGUS 
or high risk SMM (nonsymptomatic MM) improved OS (Mateos et al., 2013), but no 
therapy was suggested outside of a clinical trial (Landgren, 2013). 
Epidemiology of MGUS 
MGUS is an asymptomatic disease affecting 1 in 25 persons ≥ 50 years of age, 
and it is commonly detected by routine laboratory secondary to other medical concerns 
(Rajkumar, 2015). MGUS diagnosis is primarily made in persons aged 50 years or older, 
with increasing age correlating with a higher incidence of the condition (Agarwal & 
Ghobrial, 2013). The prevalence of MGUS is 3-4% of the adult population in the United 
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States, with males having a slightly higher incidence compared to females (Wadhera & 
Rajkumar, 2010; Landgren, Kyle, Pfeiffer, et al., 2009). However, the true incidence and 
prevalence is not known, as the condition is not routinely screened for in the “at risk” 
population of adults in the United States (Carson, Bates, & Tomasson, 2014). It is 
unlikely that a prospective study comparing detection and follow-up frequency for 
MGUS will be conducted owing to the requirements of a large sample size, long follow-
up time, and cost (Sigurdardottir et al., 2015). Additionally, any intervention, including 
watchful waiting and close monitoring, must be associated with a significant increase in 
OS with minimal or no toxicity of any type, owing to the nonsymptomatic nature of 
MGUS and the relatively low transformation of MGUS to MM requiring therapy (R. 
Kyle & Rajkumar, 2015). 
The age adjusted prevalence rate of MGUS was three times higher for Blacks 
when compared to Whites in a study of U.S. veterans (Landgren et al., 2006). Racial and 
ethnic differences in the prevalence of MGUS suggest a potential role of genetic and 
environmental factors in the development of the disease (Agarwal & Ghobrial, 2013). 
From a clinical and/or public health perspective, obesity was the only identified health 
related, modifiable factor which potentially can reduce the incidence of MGUS (Carson 
et al., 2014; Landgren et al., 2010; Rajkumar, 2015). In some studies exposure to 
pesticides was associated with a higher incidence of MGUS (Landgren, Kyle, Hoppin, et 
al., 2009; Pahwa et al., 2012; Wadhera & Rajkumar, 2010). 
A recent study sponsored by the NCI-supported Southwest Oncology Group 
(SWOG) revealed that four genes predict progression from SMM to MM, with 85.7% of 
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patients transitioning from SMM to MM in 24 months (Khan, et al., 2015). Early 
detection of high risk SMM may also be associated with earlier detection of MM and 
better outcomes, as it was demonstrated that close monitoring of MGUS resulted in 
improved OS for those with MM (Agarwal & Ghobrial, 2013; Rajkumar, 2015). The 
utility of a four-gene model to predict those who converted from SMM to MM is 
consistent with the observation that early detection of genetic changes in PCs, which 
results in transformation from MGUS to SMM to MM, may result in improved clinical 
outcomes. A limitation of the four-gene model is the need for sampling of bone marrow 
to obtain CD138+ cells (Khan, et al., 2015). 
In summary, MGUS is a premalignant condition in those aged over 50 years, with 
increased prevalence in Blacks (5.9%–8.4%) when compared to Whites (3.0%–3.6%), 
that is slightly more common in males (Wadhera & Rajkumar, 2010). MGUS transforms 
to SMM at a relatively low rate of 1% per year, over the age of 50, with some variations 
during the sixth to eighth decade of life (Rajkumar, 2015). SMM is genetically and 
clinically similar to MM (Khan, et al., 2015) but does not meet the required elements of 
the CRAB criteria, thus pharmacologic intervention is not indicated outside of a clinical 
trial (Gundrum & Neuner, 2013). MGUS is not a preventable condition, with the possible 
exceptions of the avoidance of pesticide exposure and obesity, and it is a precursor state 
of MM. 
Epidemiology of Multiple Myeloma 
The American Cancer Society reported that in 2015, approximately 26,850 
persons will be newly diagnosed with MM, with 11,240 persons expected to die from the 
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disease in the United States (American Cancer Society, 2015, p. 4). MM is thought to 
result from transformation of the premalignant plasma cells (MGUS) to MM by 
environmental and genetic factors (Rajkumar, 2015). There are no validated predictors of 
transformation from MGUS to MM that are in routine clinical practice (Alexander et al., 
2007). The median age of MM diagnosis is 65 years (Rajkumar, 2011). The prevalence of 
MM in Blacks is double the prevalence in Whites, and the disease is twice as common 
among males when compared to females (Baris, Brown, Andreotti, & Devesa, 2013). 
Globally, the highest incidence of MM occurs in Black Americans, followed by White 
Americans, with the least common incidence occurring in Asians, regardless of living in 
America (Martino, 2011). 
Data obtained from the SEER database indicate the incidence of MM is 6.3 per 
100,000 men and women, with 3.3 deaths per 100,000 based on 2008-2012 data (SEER 
Cancer Statistics Factsheets: Myeloma & National Cancer Institute, 2015). The lifetime 
risk of developing MM is 0.7% for both men and women, based on 2008-2012 data 
(SEER Cancer Statistics Factsheets: Myeloma & National Cancer Institute, 2015). MM is 
exceedingly rare in those under age 20 (Crusoe et al., 2015). There is one case report in 
the literature describing biopsy proven, symptomatic MM in a child of 8 years who 
underwent standard anti-MM chemotherapy, relapsed, was administered subsequent 
salvage therapy, and who was scheduled for allogeneic transplant (Crusoe et al., 2015). 
Non-Modifiable Risk Factors for Development of Multiple Myeloma 
Advanced age is a risk factor for MM; age adjusted incidence rates of MM 
increase with age over 40, with continued and increasing risk until the eighth decade of 
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life (Alexander et al., 2007). Development of MGUS is a risk factor for MM as it is a 
premalignant precursor to MM (Rajkumar, Gahrton, & Bergsagel, 2011). MGUS may be 
the result of pesticide exposure or other environmental exposures over the course of a 
lifetime (Landgren, Kyle, Hoppin, et al., 2009), but there is not a definitive action or 
avoidance strategy which will prevent MGUS. Early detection of MGUS is associated 
with increased survival of MM (Agarwal & Ghobrial, 2013), but this is due to close 
clinical observation. There are investigational techniques involving next generation 
sequencing (NGS) and GEP of CD138+ cells (plasma cells) to determine genetic features 
which are correlated to increased transformation to MM (Agnelli, Tassone, & Neri, 2013; 
Braggio, Egan, Fonseca, & Stewart, 2013; López-Corral et al., 2012; Mateos et al., 2013). 
The widely used technique of analyzing serum free light chains (FLCs) to determine risk 
of MGUS transformation to MM has been validated in the literature (Dispenzieri et al., 
2008). Infections, due to a defective immune system as a consequence of the disease or 
due to immunocompromised status as a result of treatment, was identified as the leading 
cause of MM related death (Blimark et al., 2015).  
Modifiable Risk Factors for Development of Multiple Myeloma 
Obesity is a modifiable risk factor associated with the development of MM; in a 
meta-analysis of prospective clinical trials, increased body mass index (BMI) correlated 
to a higher incidence of MM (Wallin & Larsson, 2011). There are sparse contemporary 
data available which report the potential of diet to impact the incidence of MM. A series 
of older studies conducted primarily with Swedish fishermen concluded that the type of 
fish (lean versus fatty) and a lack of vegetable intake were associated with MM 
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development, but these data are not representative of population level data (Martino, 
2011). Tobacco and alcohol, as variables in the development of MM, have not been 
studied in large populations and the data are not conclusive (Alexander et al., 2007). It 
should be noted that both alcohol and tobacco use have been associated with the 
development of multiple other tumor types (American Cancer Society, 2015).  
Heritability of Multiple Myeloma 
There are a number of epigenetic, genetic, transcriptional, and phenotypic 
changes associated with the development of MGUS and MM (Agarwal & Ghobrial, 
2013). The Online Mendelian Inheritance in Man (OMIM) database reported 74 
Mendelian disorders including cancer or a susceptibility to develop cancer as a 
phenotypic manifestation (McKusick, 2007). Genome-Wide Association Studies 
(GWAS) and other epidemiologic investigations have reported an increased incidence of 
MM among those who have a first degree relative with the disease (Koura & Langston, 
2013; Pruitt et al., 2014). A biological family history that includes any type of cancer is 
associated with increased MM risk overall (OR=1.73, 95% CI 1.14-2.60; P=0.008), as 
well as among African Americans (P=0.03) and participants less than 65 years of age 
(P=0.0005) (Pruitt et al., 2014). 
A limitation of many previous investigations into the role of heritability of MM 
include relatively small sample sizes in case control study designs, a lack of geographic 
diversity, and most investigations having been conducted among Whites only (Koura & 
Langston, 2013). Current research investigating genetic traits of those with MGUS and 
MM indicate that an autosomal dominant heredible hyperphosphorlyated paratarg -7 [pP-
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7] has been frequently identified in Blacks, which may be responsible for the increased 
incidence of the disease in this group of patients (Koura & Langston, 2013).  
The Role of Race in Multiple Myeloma 
Differences in the incidence and prevalence of MM between Blacks and Whites is 
amongst the most profound across all tumor types (Greenberg et al., 2015). The increased 
risk of MM among Blacks is thought to be associated with their two- to three-fold 
increase in the incidence of MGUS when compared to Whites (Landgren et al., 2014). 
Data obtained from the SEER database indicated that Blacks consistently have a higher 
incidence of MM and higher mortality from the disease when compared to other races 
(Waxman et al., 2010). Waxman et al. (2010) noted that mortality reflected the combined 
impact of cancer care and incidence, whereas survival is a measure of cancer survival. 
The increased incidence of MGUS and MM in Blacks does not correlate with poorer 
survival as a function of race or genetics, but it may reflect poorer access to care. In a 91-
subject prospective study that utilized ASCT as part of the therapeutic regimen in an 
environment where equal access to care was assured, there was no difference in survival 
outcomes by race (Verma, Howard, & Weiss, 2008). 
Among patients diagnosed with MM between 1973 and 2005, Waxman et al. 
(2010) found that Black MM patients had better disease-specific survival outcomes when 
compared to White patients (p < .001) when the patients were aged over 50 years, and 
there was no difference among races when the disease was diagnosed before 50 years 
(Waxman et al., 2010, p. 5503). In a randomized study conducted by SWOG, Black and 
White patients diagnosed with MM had equal survival outcomes when treated on either 
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of the two possible randomized treatments (Modiano, Villar-Werstler, Crowley, & 
Salmon, 1996). In a large, retrospective study evaluating the impact of race on MM 
outcomes of more than 40,000 patients, Black patients had similar survival rates 
compared to White patients by multivariate analysis (Kaya et al., 2012). 
Pathophysiology of Multiple Myeloma 
MGUS is the result of the transformation and accumulation of abnormal PCs that 
produce abnormal amounts of a single Ig. MGUS is an asymptomatic disease that is 
hypothesized to transform to MM based on multiple oncogenic events within the plasma 
cell or the bone marrow itself (Agarwal & Ghobrial, 2013). Genetic events leading to the 
development of MM include chromosome 1 abnormalities, IgH translocations, Cyclin D 
dysregulation, RAS or FGFR3 mutation, deletion of chromosome 13 and hypodiploidy 
(Agarwal & Ghobrial, 2013; Caltagirone et al., 2014; Heuck et al., 2014; Kalff & 
Spencer, 2012; Palumbo & Anderson, 2011). Although MM is a hematological 
malignancy, it is characterized by multiple genetic aberrations resulting in overexpression 
of oncogenes, loss of functional tumor-suppressor genes, which is more associated with 
solid tumor biology (Anderson, 2014) and the presence of an altered bone marrow 
microenvironment (Bam et al., 2013; Cives, Ciavarella, Dammacco, & Silvestris, 2013). 
SMM is the result of progression of MGUS (Rajkumar, Landgren, & Mateos, 
2015). SMM may be differentiated from MGUS in that it is a malignant disease, but it is 
not associated with the clinical symptoms described by the CRAB criteria (Khan, et al., 
2015; Rajkumar et al., 2015). Figure 1 illustrates the linear development from a singular, 
defective plasma cell, ending in plasma cell leukemia. MM is the result of a 
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transformation—of defective plasma cells proliferating, changing to the premalignant 
condition of MGUS, further clinical progression from MGUS to SMM, then upon 
evidence of clinical symptoms, the diagnosis of MM may be rendered, according to the 
IMWG criteria (Rajkumar et al., 2014). Plasma cell leukemia is the most aggressive 
plasma cell dyscrasia, representing systemic extramedullary MM, and it has a median OS 
of 7 months (van de Donk, Lokhorst, Anderson, & Richardson, 2012). Figure 1 illustrates 
the progression of PC expansion to symptomatic MM, ending in plasma cell leukemia. 
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Figure 2. The progression of multiple myeloma: Its pathogenesis and clinical course from 
MGUS to Plasma Cell Leukemia. From Multiple myeloma: A quick reflection on the fast 
progress by R. Hajek, 2013, InTech Publishing, http://dx.doi.org/10.5772/55366. Used 
under the Creative Commons BY 3.0 license.	  
 
MM has multiple clinical signs and symptoms requiring therapy, including bone 
pain, bone fracture, lytic lesions, anemia, renal insufficiency, increased infections, poor 
vision, back pain, DVT/PE formation, bleeding, neuropathy, and hypercalcemia (Boland 
et al., 2013; Colson, 2015). As abnormal PCs proliferate and bind to the bone marrow 
stroma, the bone marrow microenvironment secretes substances which serve as survival 
signals, including interleukin (IL)-6 and vascular endothelial growth factor (VEGF), 
which initiates angiogenesis to abnormal PCs (K.C. Anderson & Carrasco, 2011; Singhal 
et al., 1999). As a result of the proliferation of abnormal PCs occupying space within the 
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limited volume of the bone marrow and the altered bone marrow microenvironment, 
normal hematopoiesis is interrupted, resulting in the abnormally low production of 
normal components of blood, including red blood cells, white blood cells and platelets 
(Bruns et al., 2012). 
Abnormal PCs/MM cells are bound to the bone marrow stroma via intracellular 
adhesion molecules (ICAMs) (K.C. Anderson & Carrasco, 2011; Palumbo & Anderson, 
2011). The adhesion of PCs to the bone marrow stimulates bone marrow 
microenvironment changes that support abnormal PCs/MM cells by increased IL-6 
production, which is a growth factor for MM cells, increased resistance to chemotherapy, 
increased VEGF production, which initiates neovascularization to tumor cells and further 
supports their growth, and other chemokine and cytokine interactions within the bone 
marrow(K.C. Anderson & Carrasco, 2011; Johnson et al., 2014; Machal et al., 2013; 
Nishida, Yano, Nishida, Kamura, & Kojiro, 2006). As MM cells adhere to the bone 
marrow stroma they increase cell proliferation and increase anti-apoptotic proteins, and 
this adhesion then induces the bone marrow stroma to react by increasing pro-MM cell 
signals, resulting in a paracrine loop optimized for MM cell survival (Manier, Sacco, 
Leleu, Ghobrial, & Roccaro, 2012). This paracrine system loop promotes tumor survival 
and disease proliferation. This interaction between the MM cell and the bone marrow 
microenvironment and the survival advantages conveyed to MM cells via binding to the 
bone marrow stroma, allow for increased cell survival, proliferation, angiogenesis, and 
chemotherapy resistance (Mahindra et al., 2012). 
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As MM tumor volume increases, in addition to the disruption of normal 
hematopoiesis, other biological processes initiate changes and clinical sequela to the bone 
and other tissues. Under normal hematopoietic conditions, bone is remodeled constantly 
by the normal regulation of osteoblasts, which serve to support new bone development, 
and osteoclasts, which are designed to assist in bone reabsorption (Jethava et al., 2015; 
Mhaskar et al., 1996). Bone pain is frequently the clinical symptom which prompts 
medical care for MM (Kane, Hoskin, & Bennett, 2015; R. A. Kyle, Gertz, et al., 2003). 
Bone disease, evident by pain, fracture or focal lesions identified by imaging studies, is 
the net result of increased osteoclast activity resulting in bone destruction and 
hypercalcemia (Heuck et al., 2014; Mikhael et al., 2013). Bone destruction and 
reabsorption results in increased calcium in the serum (Mhaskar et al., 1996; Mikhael et 
al., 2013). Increased serum calcium (hypercalcemia) may lead to renal insufficiency, 
which is associated with early death and poor outcomes despite aggressive anti-MM 
therapy (Khan, Apewokin, et al., 2015).  
Multiple Myeloma Disease Staging and Risk Stratification 
Treatment and therapy for MM is reserved for those meeting diagnostic criteria 
for the disease (Rajkumar et al., 2014) and who have myeloma defining events, according 
to the CRAB criteria:  
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• [C] Calcium elevation in the blood (serum calcium > 10.5 mg/l or upper limit of 
normal)  
• [R] Renal insufficiency (serum creatinine >2 mg per 100 ml)  
• [A] Anemia (hemoglobin <10 g per 100 ml or 2 g < normal) 
• [B] Lytic bone lesions or osteoporosis 
Neither MGUS nor smoldering MM require anti-MM therapy, but should be 
monitored closely for the development or transformation to MM, which requires therapy 
(Anderson, 2014; Mateos et al., 2013; Palumbo & Anderson, 2011). MM is defined by 
the criteria established in the IMWG (Rajkumar et al., 2014), and it is classically 
associated with an elevation in M-protein and end organ damage. MM is stratified by risk 
to identify appropriate treatment strategies to optimize outcomes while minimizing 
toxicities and other treatment burdens. There are multiple disease risk and staging 
systems that utilize clinical, genetic, and imaging to assess risk and tumor burden at 
diagnosis and through varying stages of disease progression (Amin et al., 2014; Mikhael 
et al., 2013; van Laar et al., 2014). 
A complete response (CR) to therapy, as defined by the Bladé criteria or other 
disease response criteria, have been associated with superior clinical outcomes in a 
variety of clinical trials, including TT3 (Barlogie et al., 2014). Approximately 30% of 
patients who were able to achieve CR due to introduction of novel therapy in the 
induction and relapse treatment setting (Chanan-Khan & Giralt, 2010). A meta-analysis 
of 4,990 patients selected from both prospective and retrospective studies investigating 
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the impact of attaining a CR during induction or post-transplant, revealed CR attainment 
is associated with prolonged OS (p = < .00001) and PFS (p = < .00001) (Chanan-Khan & 
Giralt, 2010, p. 2614). Most patients relapse despite a period of CR owing to minimal 
residual disease (MRD) and intraclonal heterogeneity (Heuck et al., 2014; Papanikolaou 
et al., 2013; Sarasquete et al., 2005).  
The use of mutliparameter flow cytometry, real-time quantitative polymerase 
chain reaction (RT-PCR), and NGS enable detection of MRD (Ladetto et al., 2012; Paiva 
et al., 2008; Sarasquete et al., 2005); however, MRD detection is only appropriate in the 
research setting, has very high cost, limited therapeutic options and is not included in the 
NCCN guidelines. In one report, the majority of patients with both NDxMM and R/R 
MM were reported to be MRD + (Vij et al., 2014); however, the inclusion of patients not 
in CR confounds this finding. Most currently available techniques used for MRD 
detection require bone marrow sampling or radiography guided/directed fine needle 
aspiration of MM focal lesions. In the future, NGS based testing of peripheral blood 
without the need for paired bone marrow sampling for MRD may be viable, validated, 
and routine.  
Durie-Salmon Staging System 
The Durie-Salmon (DS) (Appendix B) staging system was published in 1975 and 
utilized measurements obtained from peripheral blood and skeletal surveys (utilizing X-
rays) to define risk and tumor burden in MM (Durie & Salmon, 1975). The DS was 
utilized in both research and clinical practice to stratify risk and prognosticate for 
survival, and it served as the standard staging system in MM for more than two decades. 
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The DS categorized MM disease stage as Stage I, II, or III, based on tumor burden, 
number of lytic lesions, and renal function (R. Kyle & Rajkumar, 2009). There are 
several known limitations to the DS including interoperator variability (in assessing the 
number of lytic lesions by radiograph), a lack of agreed and standardized laboratory 
normal values for serum creatinine and albumin, the inability to detect nonsecretory MM, 
and the lack of genetic information to inform disease risk (Greipp et al., 2005; Mikhael et 
al., 2013; Sawyer, 2011). 
EBMT Criteria 
Definitions of disease response and relapse were defined by three major 
cooperative research groups representing MM experts from the European Group for 
Blood and Marrow Transplantation (EBMT), Autologous Blood and Marrow Transplant 
Registry (ABMTR), and the International Bone Marrow Transplant Registry (IBMTR) in 
1998 (Bladé et al., 1998). The criteria published by the three groups are known as the 
Bladé criteria. ASCT as a singular therapeutic modality and in combination with novel 
therapies has been demonstrated to improve patient outcomes in MM (Anderson, 2014; 
Barlogie et al., 1997; Jagannath et al., 1997; Mikhael et al., 2013; Palumbo et al., 2011). 
The Bladé criteria established definitions of response and relapse in MM that are 
obtained using standardized methodologies and are reproducible across multiple practice 
settings. Additionally, the Bladé criteria utilized repeated measurements of MM markers 
in peripheral blood and urine, rather than repeated bone marrow aspiration to assess 
response, limited the number of bone marrow aspirations required, and further reduced 
the need of repeated radiologic examination to confirm response.  
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The Bladé criteria did not incorporate modern imaging techniques such as MRI or 
PET/CT to guide disease stage or detect extramedullary disease. The lack of modern 
imaging techniques coupled with a complex set of guidelines limited the use of the Bladé 
criteria outside of an academic setting. The Bladé criteria were utilized in the TT3 
protocols to define disease response and relapse. The IMWG guidelines for disease 
response and relapse have widely replaced the Bladé criteria and were used to define 
disease response in the TT 4, 5, and 6 clinical trials at UARK beginning in 2008. 
International Staging System 
The ISS (Appendix C) was published in 2005 and replaced the DS as the standard 
model for MM staging and risk stratification (R. Kyle & Rajkumar, 2009). The ISS 
utilizes the commonly obtained laboratory values of serum albumin and serum β-2 
microglobulin to categorize MM as Stage I, II, or III. The advantage of the ISS compared 
to the DS is the lack of interoperator variability in determining the number of lytic lesions 
by skeletal survey. Importantly, the cost of obtaining the necessary information to stage 
the disease is minimal and may be utilized throughout treatment. The ISS is validated, 
available in any modern medical practice, and is obtained by computing results from a 
peripheral blood draw.  
Limitations of the ISS include the reliance on the serum β-2 microglobulin level, 
which may be elevated simply due to renal failure or tumor burden; the ISS may not be 
utilized in the setting of MGUS or SMM; it does not utilize genetic information; and it 
has not been validated when novel therapies are administered (R. Kyle & Rajkumar, 
2009). The ISS does not consider molecularly defined risk but relies on clinical values 
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obtained from peripheral blood. The ISS is used in both the research and standard 
practice setting and is commonly reported in current clinical trials, as this practice allows 
for comparison of patients in different clinical trials (Rajkumar et al., 2014). The ISS 
does not utilize genetic information obtained from conventional cytogenetics or 
fluorescent in situ hybridization (FISH) analysis obtained from tumor cells to assess 
disease risk. The ISS was utilized as the staging system in TT3 clinical trials. 
IMWG Criteria 
The IMWG criteria for the diagnosis, staging, and risk stratification of MM were 
first published in 2003 and were last updated in 2014 (Kyle et al., 2003; Rajkumar et al., 
2014). The purpose of the IMWG criteria was to provide clinicians updated diagnostic 
and response criteria in recognition of the impact of novel therapies, improved detection 
of the disease, genetic information obtained from both conventional cytogenetics and 
FISH, new imaging techniques, and to provide a common schema to compare study 
populations (Rajkumar et al., 2014). The updated IMWG criteria were established by a 
group of MM experts representing international collaboration and were created in 
acknowledgement of the impact of novel therapies to improve OS with early intervention. 
The IMWG incorporates the use of CT, MRI, and PET-CT to detect extramedullary 
disease and the number and volume of focal and lytic bone lesions; however, the use of 
these modalities in routine practice is not recommended and is associated with very high 
cost (Anderson, 2014; McAfee, 2013; Mikhael et al., 2013). 
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Multiple Myeloma Risk Assessment 
Extending survival and attaining cure in MM result from the use of induction 
therapy, high dose therapy followed by ASCT, consolidation, and maintenance therapy, 
although cure is relatively uncommon and is only possible in approximately 10% of 
patients with existing therapy (Barlogie et al., 2014; Hajek, 2013). Host-related risk 
factors include age, performance status, renal function, SES, and potentially distance 
from home to the site of cancer care (Greipp  et al., 2005; Lenhard et al., 1987; Meilleur 
et al., 2013; Mikhael et al., 2013; Paul et al., 2013). Tumor-related risk factors include the 
genetic abnormalities observed in tumor cells, involving hyperdiploid/nonhyperdiploid 
status, alteration or deletion of chromosome 1,13 or 17, and other chromosome 
abnormalities (Furukawa & Kikuchi, 2015; Greipp et al., 2005; Mikhael et al., 2013; 
Sawyer, 2011; Van Wier et al., 2013).  
MM survival is correlated with the depth of response to therapy measured by the 
attainment of CR. Therapy and other variables including genetic risk observed in the 
tumor cell by various techniques impact the achievement and duration of CR including 
patient age, renal function, serum albumin level, serum β2-microglobulin; ISS stage, and 
potentially patient distance to their site of care (Greipp et al., 2005; Kapoor et al., 2010; 
Lenhard et al., 1987; Lipe et al., 2012; Mikhael et al., 2013; Morgan, Walker, & Davies, 
2012). Risk stratification should be performed to identify patients who are at high risk of 
early progression due to aggressive disease associated with high risk features described 
below and not for treatment decisions (Rajkumar, Harousseau, et al., 2011). 
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Risk stratification methodologies based on information available by measurement 
of albumin, β2-microglobulin, C-reactive protein, and lactate dehydrogenase (LDH) 
obtained from peripheral blood have been validated, are consistent across multiple 
laboratories, and are relatively inexpensive (Bataille, Boccadoro, Klein, Durie, & Pileri, 
1992; Greipp et al., 1993; Greipp et al., 2005; Patel et al., 2012). The ISS stage is 
determined by obtaining serum levels of albumin and β2-microglobulin, which are 
readily measured from peripheral blood utilizing standard laboratory examination that has 
been widely adopted in both research and clinical practice (Anderson, 2014; Rajkumar et 
al., 2014). Strengths of the ISS and other methods to evaluate risk based on laboratory 
values obtained from peripheral blood include low cost, standardized measurement, 
simply calculated risk assessment, and a noninvasive approach. Limitations to risk 
assessment utilizing peripheral blood sampling include the lack of genetic information to 
inform risk, the inability to monitor plasma cell cellularity within the bone marrow, and a 
lack of radiographic evidence of disease progression or response to therapy. 
Genetic information has been demonstrated to provide valid prognostic 
information and as a result, the NCCN and other organizations recommend risk 
stratification by a variety of genetic testing methods, including conventional karyotyping 
and FISH (Anderson, 2014; Kapoor et al., 2010; Mikhael et al., 2013). A more detailed 
review of genetic testing of MM based on testing methodology will be provided. 
Genetically Defined Risk 
MM is a genetically diverse disease noted for complex cytogenetics, multiple 
genetic aberrations, and intraclonal heterogeneity, which change due to time and selective 
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pressure of therapy (Heuck et al., 2014; Morgan et al., 2012). Although MM is thought to 
arise from a single mutated plasma cell, it is recognized that progression from MGUS to 
symptomatic MM involves multiple genetic changes in multiple plasma cell clones 
(Morgan et al., 2012). This intraclonal heterogeneity evolves over time, due to host and 
tumor biology. Bone lesions and/or extramedullary foci of MM vary by anatomical site, 
such that a sample obtained from one anatomical location may have different genetic 
features when compared to another sample obtained from the same patient, at the same 
point in time, from another site (Lohr et al., 2014). There is no single genetic alteration 
that characterizes MM for diagnostic purposes (Keats et al., 2003). 
MM may be categorized genetically into two groups, hyperdiploid (≥ 47 and < 75 
chromosomes) or nonhyperdiploid based on the number of chromosomes detected in 
CD138+ plasma cells (Van Wier et al., 2013). Non-hyperdiploid MM is clinically more 
aggressive than hyperdiploid MM, and it is associated with shorter PFS and OS (Mikhael 
et al., 2013; Van Wier et al., 2013). Investigators at the Mayo Clinic cite ploidy status as 
hyperdiploid or nonhyperdiploid in the stratification of risk in MM (Mikhael et al., 2013). 
Diploid status is not detectable utilizing conventional cytogenetics, thus more advanced 
pathologic techniques, including FISH or GEP, are required to quantify this known risk 
factor in individual patients (Keats et al., 2003). The mechanisms of hyperdiploid plasma 
cell transformation are not well described, but it is reported that the most common 
hyperdiploidy is trisomy 11, which is implicated in cyclin D1 overexpression (Furukawa 
& Kikuchi, 2015). Importantly, biologic samples used to determine ploidy status must 
originate from tumor samples and may not be obtained from peripheral blood. 
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Gender in MM 
The Medical Research Council (MRC) is a United Kingdom (UK) based research 
collaborative that supports and conducts research in a variety of medical disciplines. The 
MRC Myeloma IX trial evaluated long-term outcomes of N = 1970 patients with MM in 
the UK, a planned analysis of gender disparities and tumor genetics in MM indicated that 
the low risk genetic feature of hyperdiploidy status was discovered in 62% of males and 
50% females (p = .001) and secondary genetic defects, including the high risk feature 
del(13q) were more frequent in 52% of females and 41% of males (p = .042) (Boyd et al., 
2011). Female gender was associated with inferior OS, 44.8 months for females and 49.9 
months for males (p = .0.020) (Boyd et al., 2011).   
In contrast to the findings of the MRC Myeloma IX trial, an analysis of data 
collected from more than 1200 participants treated at UARK through 2010, did not reveal 
any adverse prognostic impact of female gender (Szymonifka et al., 2010). PFS and OS 
stratified by gender are not routinely reported in the literature although the numeric 
frequency of the disease in males is reflected in clinical trial reports. There are no data in 
the peer-reviewed literature indicating any drug or treatment regimen is more or less 
effective based on gender. The potential of gender to influence PFS and OS outcome in 
NDXMM is not well described in the literature. 
Age as a Risk Factor in MM 
MGUS, the likely obligate precursor to MM is associated with increasing age and 
is reported in 5% of all adults aged over 70 years (Mikhael et al., 2013). MM is regarded 
as a diagnosis of older persons, with the incidence of the disease increasing with 
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increased age; older age is a prognostic risk factor according to multiple treatment and 
diagnostic guidelines (Kristinsson, Anderson, & Landgren, 2014; Mikhael et al., 2013). 
Age is a recognized prognostic variable for consideration for ASCT. ASCT is a standard 
therapy for patients who qualify for the procedure based on performance status; 
performance status is independent of chronologic age in the Karnofsky and ECOG 
performance status criteria (Eastern Cooperative Oncology Group, 2015; National Cancer 
Institute, 2015a). In consideration of available evidence, the Centers for Medicare and 
Medicaid Services, has limited the availability of ASCT to persons under the age of 77 
years who have adequate performance status and meet other eligibility criteria for the 
procedure. Age over 77 years is a disqualifying factor based on current Medicare 
guidelines regarding coverage for ASCT in MM (Hill, 2000). The age limit for Medicare 
payment for ASCT may be viewed as problematic as the median age of MM diagnosis is 
reported to be between 65-70 years and 35-40% of patients are older than 75 years at 
diagnosis (Zweegman, Palumbo, Bringhen, & Sonneveld, 2014). 
The introduction of novel therapy has increased PFS and OS for most patients; 
however, patients with GEP70 defined HRMM and persons over the age of 65 have not 
benefitted robustly from the introduction of new therapeutics and advances in supportive 
care (Kumar et al., 2008; Usmani et al., 2012; Zweegman et al., 2014). In one study, 
French and Italian patients ≥ 75 years who were treated with novel therapy were found to 
have equal OS outcomes compared to historic controls (Zweegman et al., 2014). It has 
been noted that although there are genetic differences in tumors noted between younger 
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and older patients with MM, these differences do not correlate with more aggressive 
disease (Zweegman et al., 2014). 
Gene Expression Profiling in MM 
GEP is an analysis of the genes from CD138+ plasma cells, obtained from bone 
marrow sampling, to stratify the risk of MM progression. GEP is not included as a 
standard of care in the diagnosis or monitoring of MM in clinical practice (Anderson, 
2014), but this technique is utilized in the research setting and at some tertiary care 
facilities that have a research interest in MM (Decaux et al., 2008; Mikhael et al., 2013; 
van Laar et al., 2014; Zhan et al., 2002). The GEP70 model has been validated as an 
independent predictor of disease risk in both newly diagnosed and relapsed/refractory 
MM (Shaughnessy et al., 2007; van Laar et al., 2014). GEP-based risk stratification is 
superior to FISH, conventional cytogenetic, or serum based risk stratification schemas 
(Mikhael et al., 2013; van Laar et al., 2014).  
The GEP70 model was created at UARK and has subsequently been licensed to 
Signal Genetics, Inc., as the MyPRS® test (van Laar et al., 2014). In the research setting 
at UARK, the GEP70 model is performed by UARK staff and serves as the prospective 
risk stratification methodology in all Total Therapy Trials beginning with TT4, although 
the ISS is also utilized to provide information on patient risk. MyPRS® is available as a 
clinical test to any clinician who is authorized to order the exam and able to provide a 
bone marrow aspirate. There is no significant difference in risk scores between the test as 
performed by UARK versus using the MyPRS® test (van Laar et al., 2014). 
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GEP is a molecular examination of tumor cells performed on purified CD138+ 
cells obtained from bone marrow or bony focal lesions; the test has not been validated 
utilizing peripheral blood and in contrast to the ISS, it is an invasive test. Microarray 
analysis utilizing the Affymetrix U133Plus 2.0 chip and computation of genetic 
information identified 51 up-regulated genes and 17 down-regulated genes that are 
predictive of high risk and low risk MM disease (Shaughnessy et al., 2007). The GEP70 
score is highly predictive of both PFS and OS and has been utilized in clinical trials that 
were submitted to the U.S. FDA in support of the approval of bortezomib in MM 
(Jagannath et al., 2006; Richardson et al., 2007). 
GEP70 performed at UARK results in a numeric score indicative of MM risk. As 
described by Shaughnessy and associates, a GEP70 score ≤ 0.66 is indicative of low risk 
disease and a score ≥ 0.661 indicates high risk disease on an open-ended 
scale(Shaughnessy et al., 2007). The 5-year event free survival for those with newly 
diagnosed GEP70-defined low risk disease is 60% compared to 18% for high risk 
disease, p < .001, HR = 4.51; 5-year OS in low risk disease is 78%, contrasted to 28% in 
high risk disease, p < .001, HR = 5.16 (Shaughnessy et al., 2007, p. 2279). GEP70-
defined high risk disease represents approximately 13% of all cases (Shaughnessy et al., 
2007). 
Limitations of GEP-based risk stratification for MM include the need for bone 
marrow sampling, extensive sample preparation, a lack of agreement in the peer-
reviewed literature regarding ideal candidate genes for risk assessment, and a lack of 
therapy-specific response signatures by GEP (Amin et al., 2014; Anderson, 2014; van 
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Laar et al., 2014). The NCCN currently identifies GEP as a research procedure; as a 
result, GEP utility is limited and not used in routine practice. The mSMART guidelines 
for the treatment of MM, published by investigators from the Mayo Clinic, also identify 
GEP as an investigational test (Mikhael et al., 2013). 
GEP-Defined Molecular Subgroups 
Investigators at UARK utilized GEP to identify seven genetically distinct 
subgroups of MM (Zhan, Huang, et al., 2006). In a group of 414 patients with NDxMM 
who went on to receive high dose therapy followed by tandem ASCT, GEP of CD138+ 
plasma cells identified seven unique gene expression signatures associated with different 
clinical consequences and statistically significant differences in PFS and OS (Zhan, 
Huang, et al., 2006). GEP-defined subgroups have been utilized to guide therapy based 
on genetic risk and expected clinical course in both NDxMM and R/R MM at UARK. 
According to Zhan and associates (2006), HY, CD-1, CD-2, and LB subgroups have been 
correlated with improved PFS and OS when compared to the PR, MS, and MF subgroups 
(see definitions below). 
GEP-based subgroups are not utilized for disease stratification outside UARK—
they are used exclusively for research purposes elsewhere. Identification of a response 
signature to bortezomib has been accomplished at UARK (Shaughnessy et al., 2011) 
based on GEP-defined molecular subgroups. The identification of patients who respond 
by MS is only applicable to those who are treated at UARK on TT research protocols.  
 CD-1: Multiple Myeloma subgroup characterized by overexpression of 
Cyclin D1 (CCND1), Cyclin D3 (CCND3), and the Kelch-like 4 (KLHL4) gene. 
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 CD-2: Multiple Myeloma subgroup characterized by overexpression of 
CCND1 and CCND3, as well as MS4A1/CD20 and the early B cell marker, PAX5.  
 Hyperdiploidy (HY): Multiple Myeloma subgroup characterized by 
trisomies of odd number chromosomes, not including chromosome 1.  
 Low Bone (LB): Multiple Myeloma subgroup characterized by low bone 
disease, defined by a low number of MRI-defined focal lesions. 
 MF: Multiple Myeloma subgroup characterized by an overexpression of 
the c-MAF and MAFB proto-oncogenes.  
 MS: Multiple Myeloma subgroup characterized by MMSET 
overexpression, with or without overexpression of FGFR3.  
 Proliferation (PR): Multiple Myeloma subgroup characterized by 
overexpression of cell proliferation genes and a high cell proliferation index.  
Risk Assessment by Conventional Karyotyping  
It has been established that risk associated with MM can be, at least in part, due to 
the genetics of the myeloma cell (Morgan et al., 2012; Peterson, Chavan, Bauer, Heuck, 
& Johann, 2014; Sawyer, 2011; Zhuang et al., 2014). Hyperdiploid MM is associated 
with lower risk disease (Van Wier et al., 2013; Zhan, Huang, et al., 2006). In a large 
study of the genetics of MM, Blacks were found to have more frequent hyperdiploid 
disease than Whites and less frequent chromosomal translocations, including t(11;14) or 
t(4;14) that are associated with high risk disease (Greenberg et al., 2015; Kalff & 
Spencer, 2012; Keats et al., 2003). The NCCN guidelines for the diagnostic workup of 
MM include conventional karyotyping analysis by cytogenetic examination and FISH 
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examination of tissue obtained from a bone marrow biopsy (Anderson, 2014). Metaphase 
cytogenetic (conventional karyotyping) examination is performed on dividing MM cells 
which have been isolated from bone marrow and cultured in vivo. The bone marrow and 
bone marrow microenvironment support the growth, proliferation, and division of MM 
cells (Bam et al., 2013; Johnson et al., 2014; Palumbo & Anderson, 2011). When 
removed from the supportive bone marrow microenvironment, approximately 33% of 
MM cells will continue to divide; these cells have complex cytogenetic features and are 
associated with aggressive disease (Zhan, Sawyer, & Tricot, 2006).  
There are known limitations of conventional cytogenetic analysis. Nearly 70% of 
all MM cells will not yield any results by cytogenetic examination, as they will not divide 
outside of the bone marrow; thus, meaningful information cannot be derived from the 
vast majority of samples obtained. There are other drawbacks of cytogenetic 
examination, including the necessity of tissue obtained by bone marrow biopsy, the 
expertise needed to prepare a sample for examination, and the costs associated with this 
specialized test (Anderson, 2014; Mikhael et al., 2013). Disease risk assessed by 
cytogenetic examination is based on the deletion of chromosome 13 and detection of 
complex karyotypes (Mikhael et al., 2013). 
Risk Assessment Using Fluorescence in situ Hybridization (FISH) 
FISH-based cytogenetic testing does not require actively dividing cells and 
therefore may be performed on appropriately prepared CD138+ cells obtained from bone 
marrow biopsy (Ross et al., 2012). FISH testing is intended to reveal specific genetic 
abnormalities that have been implicated in risk stratification, and this test should be used 
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in conjunction with conventional cytogenetic testing (Anderson, 2014). The routine use 
and widespread availability of FISH testing in MM has revealed that the true incidence of 
genetic abnormalities in MM is much higher than previously understood utilizing classic 
cytogenetics (Ross et al., 2012). If a clinician is unable to obtain both FISH and classic 
cytogenetic test results from bone marrow biopsy, FISH is the preferred test, owing to its 
specificity and accuracy and the impact of specific genetic abnormalities which may be 
identified by FISH but not by classic cytogenetic analysis (Mikhael et al., 2013). In Table 
2, FISH-based detection of specific genetic abnormalities and their relative frequency are 
described from a group of 484 patients with NDxMM treated at the Mayo Clinic (Kumar 
et al., 2012). 
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Table 2 
 
Genetic Abnormalities Detected by FISH (N = 484) 
 
FISH abnormality Frequency n (%) 
Any translocations 22 (46) 
t(11;14) 86 (18) 
t(4;14) 47 (10) 
t(14;16) 24 (5) 
t(6;14) 3 (<1) 
t(14;20) 1 (<1) 
Other IgH locus abnormality 59 (12) 
Any trisomy 275 (57) 
1 chromosome 42 (9) 
2 chromosomes 1 
3 chromosomes <1 
4 chromosomes 7 
≥ 5 chromosomes 60 (12) 
Monosomy 236 (49) 
Monosomy 13/Del 13q 228 (47) 
Monosomy 14 38 (8) 
Monosomy 16 14 (3) 
P53 abnormality 62 (13) 
Del 17p 49 (10) 
Other (all tetraploidy) 3 (<1) 
Normal 15 (3) 
Note. Adapted from “Trisomies in multiple myeloma: impact on survival in patients with 
high-risk cytogenetics” by Kumar et al., 2012, Blood, 119(9), p. 2101. Copyright 2013, 
American Society of Hematology. 
 
High Risk MM 
The designation of HRMM for those with NDxMM, based upon genetic features 
of plasma cell clones, may be accomplished utilizing different methods including FISH, 
GEP, and NGS (Bianchi et al., 2014; Heuck et al., 2014; Mikhael et al., 2013; Palumbo et 
al., 2011). In addition to the ploidy status of the disease by chromosome counts, specific 
genetic mutations are associated with high risk disease. The frequency of HRMM varies 
by detection method, but it is reported to impact between 10% and 20% of patients at 
initial diagnosis (Bianchi et al., 2014). PFS and OS outcomes for those with HRMM are 
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significantly shorter when compared to LRMM (Greenberg et al., 2014). The proteasome 
inhibitor bortezomib has been shown to abrogate the risk associated with t(4;14), which is 
a commonly detected genetic feature in HRMM (Anderson, 2014; Sawyer, 2011; 
Sonneveld et al., 2012). 
Impaired Renal Function 
Impaired renal function occurs frequently in MM due to the excretion of high 
amounts of calcium, protein, and light chains in blood, which causes damage and 
decreased functioning of the renal tubules (Khan, Apewokin, et al., 2015; Tosi et al., 
2015). As tumor burden increases, the amount of defective plasma cells which excrete 
light chains also increases; as light chain levels increase this induces the increased 
production of the pro-inflammatory and pro-MM cytokines IL-6 and tumor necrosis 
factor alpha (TNF-α) (Anderson, 2014; Tosi et al., 2015). Therapy intended to treat MM 
may also contribute to impaired renal function due to tumor lysis syndrome, whereby the 
cellular contents of plasma cells destroyed by therapy are carried into the renal tubules by 
blood, resulting in renal tubule trauma (Tosi et al., 2015).  
Unregulated bone reabsorption due to an increase in osteoclast activity results in 
bone destruction, pain, and increasing serum levels of calcium (Palumbo & Anderson, 
2011). Treatment with bisphosphonate drugs has been demonstrated to prevent and treat 
bone events in MM and has been incorporated into the standard of care (Anderson, 2014; 
Mhaskar et al., 1996; Schmitt et al., 2013). Bisphosphonate drugs are inhibitors of 
osteoclasts and have been demonstrated in multiple clinical trials and in a Cochrane 
Systematic review to reduce fractures and pain associated with symptomatic MM 
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(Mhaskar et al., 1996). The toxicities associated with bisphosphonate therapy include 
hypercalcemia, osteonecrosis of the jaw, and renal toxicity (Schmitt et al., 2013). 
Patient Distance Traveled as a Risk Factor 
Studies assessing the impact of patient distance traveled in other tumor types have 
demonstrated a correlation between increasing distance traveled and the type of therapy 
received (Lamont et al., 2003; Wheeler et al., 2014). A review of the literature reveals 
inconsistent patient populations studied when assessing the potential of distance to 
impact patient outcomes with MM. Contributing to the confounding conclusions drawn 
from previous studies associating distance with risk in MM are data obtained prior to the 
availability of novel agents, methodological errors, small patient populations studied, the 
retrospective nature of many studies, a lack of consistent measurements of socioeconomic 
status, and short follow-up (Abou-Jawde et al., 2006; Colson, 2015; Lenhard et al., 1987; 
López-Corral et al., 2012; Ojha et al., 2007; Paul et al., 2013; Shank, Brown, & Schwartz, 
2015; Tariman et al., 2014). 
Socioeconomic status (SES) has an impact on cancer survivorship across all 
tumor types (Chang et al., 2012; Siegel, Naishadham, & Jemal, 2012). Socioeconomic 
data were not collected in the TT3 trials and data are not available to characterize 
individual patients who were enrolled. Furthermore, it is a known limitation of this study 
that a number of TT3 protocol participants did temporarily relocate to Little Rock for at 
least a portion of their treatment. The lack of SES data in this study is a recognized 
limitation. Demographic data obtained at the U.S. zip code level are available but are 
inconsistent and do not adequately characterize financial or social factors at an individual 
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level (Berkowitz, Traore, Singer, & Atlas, 2015). It has been reported, that in diffuse 
large B cell lymphoma, another hematologic malignancy, that poorer economic status 
negatively impacts survival (Flowers & Nastoupil, 2014; Tao, Foran, Clarke, Gomez, & 
Keegan, 2014). SES status may be measured by cash on hand, education level, access to 
care, zip code of residence, and the number of persons living in a domicile, but none of 
these measures is adequate in a population-level study (Khera, 2014; Paul et al., 2013). 
Further confounding the interpretation of SES as a predictor of risk in cancer is the 
variability of care and services available in rural areas when compared to tertiary care 
centers in urban environments (Meilleur et al., 2013; Wheeler et al., 2014). In care 
settings where universal access to health care is available, it has been reported that poorer 
economic status is still associated with poorer survival (Landgren et al., 2006; Tariman et 
al., 2014). 
The effect of distance traveled to care site on survival of patients with cancer was 
assessed in an NCI-supported study that collected data on 240,531 patients at 21 
comprehensive cancer centers from 1977-1982 (Lenhard et al., 1987). Among these 
patients, 1,479 had an MM diagnosis. Consistent with other reports in the MM literature, 
Lenhard and associates (1987) reported that among the MM subjects included in their 
manuscript the median age at diagnosis was 63.6 years, with more male and White 
patients (Baris et al., 2013; Hajek, 2013; Lenhard et al., 1987). In both univariate and 
multivariate analysis, Lenhard and associates (1987) reported patients who lived ≥ 150 
miles from the site of cancer care had significantly improved OS (p = .007). The 
investigators noted a trend consistent with increasing distance from the site of care 
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correlating with increased OS, even when controlling for all other known covariates, 
including SES. As reported by Lenhard and colleagues (1987), distance has an impact on 
OS. In the context of a literature review performed in 2015, these data must be 
interpreted with the knowledge that MM therapy, in the measured time frame, did not 
incorporate novel agents, that generally all therapy was delivered intravenously and 
although the study did report data from a generally representative population of those 
with MM, there was the potential for selection bias as only data from comprehensive care 
centers were included in the research. It is possible that the necessity for intravenous 
delivery of chemotherapy also introduced selection bias favoring patients with better 
performance status. Further limiting the utility of these results is the lack of patient 
staging according to the DS criteria. The lack of DS staging data in the report impairs 
interpretation of findings, as the ability to travel due to advanced stage disease may have 
impacted subject participation and therefore may have enriched the study with patients 
who had a lower disease burden. The finding that distance does have an impact on OS in 
MM has prompted others to further investigate this finding. 
In a study conducted by a group of MM experts from the Cleveland Clinic, 
neither subject race, SES, nor distance traveled to the site of care were found to be 
significant prognostic factors for OS in both NDxMM and R/R MM (Abou-Jawde et al., 
2006). The study reported OS outcomes for 292 patients with NDxMM and 124 with R/R 
MM in a retrospective fashion and included patients who were treated both on and off 
research protocols. The report by Abou-Jawde and associates (2006) did utilize SWOG 
patient staging criteria and also included information on serum albumin and β2-
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microglobulin that are consistent with other published reports. The research as presented 
has several limitations. The data that informed the research were obtained from both 
newly diagnosed and relapsed refractory patients. The inclusion of R/R MM patients in 
the analysis naturally shortens OS, owing to disease that is refractory to therapy, and thus 
limits the interpretation of the data.  
Second, the research did not include patients who received the standard of care 
during the years of study data collection, which included induction chemotherapy 
followed by ASCT (no patients in this report underwent ASCT). Importantly, there were 
no data reported on the number and type of genetic abnormalities in patients, which 
further limits the application of this information into research or clinical practice. It is 
unknown if there was selection bias favoring those with high risk disease or poor 
performance status, as data concerning cytogenetic risk and the ability to meet criteria for 
ASCT were not reported. The use of novel agents was limited to thalidomide in this 
report, although the Cleveland Clinic did have access to bortezomib on a commercial 
basis. The use of bortezomib in genetically defined high risk patients was known to 
mitigate the impact of t(4;14) when the data were reported. Bortezomib is only 
administered by needle; the necessity for a venous access line or the impracticality of 
travel to receive a subcutaneous injection may have further biased patient selection in this 
trial. Abou-Jawde and colleagues (2006) reported that race had no prognostic impact on 
OS, yet only 13% of trial participants were Black. The small number of Black patients 
included in the trial and the inclusion of both NDxMM and R/R MM patients limit the 
impact of the report. 
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In a rejoinder to the report by Abou-Jawde and associates (2006), errors in study 
methodology include over-controlling for the influence of serum albumin and β2-
microglobulin as independent prognosticators of risk, as they are included in the SWOG 
disease staging system, a general lack of valid epidemiologic methods, and insufficient 
power to detect statistically significant changes (Ojha et al., 2007). The inclusion of both 
NDxMM and R/R patients in a Cox proportional hazard model is methodologically 
inappropriate as the survival probabilities are not constant (Ojha et al., 2007). The lack of 
genetically defined risk factors was not noted in the rejoinder, but the lack of other 
prognostic information, including LDH levels, was noted. 
The most recent peer-reviewed report investigating the potential impact of patient 
distance traveled on outcome in MM was conducted by investigators from the NCI-
designated comprehensive cancer center located at Dartmouth Hitchcock medical center 
(Lipe et al., 2012). In a retrospective analysis of 77 consecutive patients with NDxMM 
who underwent ASCT, increasing distance from the cancer center was associated with 
improved OS (p = .004) but had no impact on PFS (p = .26) (Lipe et al., 2012). In 
contrast to other reports, the novel agents thalidomide, lenalidomide, and bortezomib 
were utilized in the majority (69%) of patients (Lipe et al., 2012). Among these 77 
patients, the median OS for those who lived > 50 miles from the medical center was 81.6 
months compared to 50.4 months for those who lived < 50 miles from the site (p = .03). 
The investigators utilized the ISS to categorize risk but they did not analyze genetic data, 
which limits the interpretation and application of these data. Limited genetic information 
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was included in the report but was not included as a variable in the Cox regression model 
that was used to evaluate the relationship between distance and OS.  
The authors reported several limitations of the study, including the small number 
of patients studied over a 7-year accrual period, the lack of a consistent pre-transplant 
induction regimen, and referral bias (Lipe et al., 2012). The investigators concluded that 
distance from the transplant center should not be considered a negative prognostic 
variable for transplant, but the investigators did not address the question in a 
nontransplant population. Table 3 presents selected features of risk categorized by patient 
factors, tumor biology and tumor burden. 
Table 3 
 
Selected Risk Features in MM 
 
Patient	  Associated Tumor	  Biology	  Associated Tumor	  Burden	  Associated 
Physical Health / 
Performance Status 
Ploidy Status Extramedullary Disease 
Age Alterations on Chromosome 
1 
Plasma Cell Proliferation 
Rate 
Renal Function Deletion of Chromosome 
13 by Conventional 
Karyotyping 
Serum β2-microglobulin 
Level 
Distance from site of care+ High Risk GEP Score Serum Albumin Level 
 17p – (p53 deletion) Serum LDH Level 
 t(4;14)  
 t(6;14)  
 t(11;14)  
 t(14;16)  
Note. Adapted from “Management of newly diagnosed symptomatic multiple myeloma: 
Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) 
Consensus Guidelines 2013”. Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. 
K., Hayman, S. R., … Lacy, M. Q. (2013).  Mayo Clinic Proceedings, 88(4), 360–376. 
Copyright, 2013, Mayo Foundation for Medical Education and Research. 
+ Investigational Variable 
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CRAB Criteria - Laboratory and Clinical Information  
The CRAB criteria are associated with laboratory findings and clinical symptoms 
defined by the IMWG (Kyle et al., 2003).  
Elevated Calcium: Serum calcium levels are elevated in MM due to the imbalance 
between osteoblasts and osteoclasts. Osteoclasts are associated with increased bone 
reabsorption, resulting in excess calcium being released into the serum. Excess serum 
calcium may lead to hypertension, weakness, altered mental status, cardiac arrest, and 
renal failure (Levey & Coresh, 2012). 
Renal Dysfunction: Renal dysfunction in MM is caused both by elevated serum 
calcium in the serum and interstitial nephritis caused by excess κ and λ light chains 
(FLC) being deposited in the glomerulus of the kidney (Anderson, 2011; Khan, 
Apewokin, et al., 2015; Miguel & Mateos, 2011). Renal dysfunction is associated with 
poor survival (Khan, Apewokin, et al., 2015) and is complicated by the use of 
pharmacologic agents intended to treat the disease which cause significant renal 
impairment, including bisphosphonates (Mhaskar et al., 1996; Schmitt et al., 2013; Tosi 
et al., 2015). 
Summary and Transition 
Normal PCs are terminally differentiated B cells that serve to produce and secrete 
antibodies, a critical component of human humoral immunity to pathogenic organisms. 
Genetic and host factors are thought to contribute to changes in PCs which lead to 
mutations causing the abnormal proliferation of a single PC, giving rise to an expanding 
number of PC clones. Clonal expansion occurs within the bone marrow but does not 
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cause clinical signs or symptoms of disease. Expanding PC clones that meet the criteria 
established by the IMWG are known as MGUS. 
MGUS is a premalignant condition, generally occurring in persons older than age 
50 that is often diagnosed when medical care is sought for other reasons. Genetic and 
epigenetic originated mutations to PC clones may lead to the development of MM, 
although the risk of conversion from MGUS to MM only occurs at the rate of 1% per 
year. There is no known behavior or therapy that can prevent the conversion of abnormal 
PCs to MGUS or to MM. MGUS disproportionally affects Blacks compared to Whites 
and is more common in males compared to females. The heritability of MGUS and MM 
is not well established in large trials, but there is evidence that the conditions are more 
common in persons that have a first-degree relative with the conditions. 
MM causes pain, anemia, and skeletal fractures and is diagnosed according to the 
IMWG criteria; therapy is indicated when the CRAB criteria are met. Therapy is 
complex, involves the administration of multi-agent chemotherapy and novel therapies, 
ASCT in patients who are able to undergo the procedure, and maintenance therapy. MM 
is staged according to multiple schemas, including the DS, ISS, and IMWG. MM risk is 
stratified according by ISS, GEP, FISH, and cytogenetic tests, with each methodology 
having known strengths and weaknesses. 
With appropriate therapy LRMM is associated with median OS of 8 –10 years, 
with HRMM having a median OS of less than 3 years (Mikhael et al., 2013). Projected 5-
year and median PFS and OS vary by risk stratification methodology. The standard of 
care dictates that conventional cytogenetics and FISH studies be performed in NDxMM 
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to identify the genetically identified risk factors associated with HRMM. GEP is a more 
advanced methodology to describe genetic features of the disease, but it is associated 
with higher cost and is currently considered by NCCN to be an investigational test.  
Non-genetic/nontumor related risks in MM include impaired renal function, older 
age, and potentially distance traveled to obtain care for the disease. Age, renal 
dysfunction, and poor performance status are known risk factors for early disease 
progression and shorter response to MM therapy and may limit treatment options, 
including ASCT. Multiple investigations have been completed that examined the impact 
of distance on PFS and OS for those with cancer, including MM. A current literature 
review focusing on the impact of distance as a prognostic variable revealed inconsistent 
findings and nonrepresentative populations studied. This study sought to address a gap in 
the contemporary literature regarding the potential impact of distance traveled to obtain 
care on PFS and OS in NDxMM in the era of novel therapy followed by ASCT and 
maintenance therapy. 
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Chapter 3: Research Method 
Introduction 
The purpose of this quantitative study of 480 clinical trial participants was to 
investigate the impact of patient distance from the site of care on survival outcomes for 
patients enrolled on two clinical trials for newly diagnosed multiple myeloma (NDxMM). 
Multiple Myeloma (MM) is a hematologic malignancy resulting from clonal expansion of 
defective plasma cells leading to organ damage, skeletal fractures, anemia, and other 
clinical symptoms. The following sections describe the research design, study setting and 
sample, Total Therapy 3 (TT3) entry criteria, including baseline blood chemistry values, 
and bone marrow biopsy proven, NDxMM, data acquisition, description of variables, 
proposed statistical procedures and ethical considerations and protection of participants’ 
rights in the study. 
Research Design 
This study was a quantitative, retrospective analysis of secondary data obtained 
from the TT3 at The Myeloma Institute for Research and Therapy located at the 
University of Arkansas for Medical Sciences that enrolled patients with NDxMM. The 
data to inform this study were collected from prospective clinical trials for those with 
NDxMM conducted at MIRT. This study and the original TT3 trials investigated 
progression free survival (PFS) and overall survival (OS) outcomes utilizing the Bladé 
criteria to define disease progression. The dependent variables are PFS and OS. 
Independent variables include close proximity to MIRT based on patient zip code at TT3 
study registration, gender, age ≥ 65 years, GEP70-defined risk status (HRMM or 
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LRMM), and ISS stage. Prospective clinical trials utilizing standardized criteria to 
evaluate disease response allow a researcher to a priori collect all information necessary 
to answer the primary objectives of the clinical trial. In TT3, disease staging and 
responses were conducted utilizing the ISS and EBMT criteria respectively.  
A retrospective cohort design was selected as the most appropriate design for this 
study due to the time and logistical requirements to prospectively accrue data. 
Retrospective trial designs to evaluate the investigational variable of patient distance 
traveled on PFS and OS outcomes are appropriate. The earlier TT3 trials prospectively 
collected data for PFS and OS outcome measurement. The independent variables include 
patient distance traveled, GEP70 status, ISS stage, gender, and age ≥ 65 years. 
Confounding variables include a lack of SES data and minor differences between TT3a/b. 
All 480 participants provided written informed consent for treatment and research 
purposes on TT3, which was conducted under the auspices of UARK IRB approval and 
was subject to FDA oversight. The TT3 protocols were also subject to review by an 
independent Data Safety and Monitoring Board to ensure participant safety and 80% of 
subject records were subjected to audit for attribution of toxicity, response, and response 
duration. The NCI supported the TT3 protocols via grant CA 55813. 
Setting and Sample 
The TT3 clinical trials are among the largest prospective clinical trials (N = 480) 
that have investigated PFS and OS in NDxMM patients who underwent induction therapy 
with novel agents, tandem ASCT, and multidrug maintenance therapy. Clinical data, PFS 
and OS outcomes continue to be collected from patients that enrolled on TT3 trials and 
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are still alive. The updated data are entered into the clinical record and MMDB at UARK. 
The research participants in the studies are persons with NDxMM, aged ≥ 18 years, who 
met the eligibility criteria, and enrolled on TT3. The TT3a/b trial designs were similar 
although there are slight differences in the maintenance portions of the trials. TT3a 
mandated that bortezomib be administered in combination with thalidomide and 
dexamethasone in the maintenance phase of the study in year 1 only, in maintenance 
years 2-3, only thalidomide and dexamethasone were to be administered. In TT3b, 
bortezomib was administered in combination with lenalidomide and dexamethasone in all 
3 years of maintenance. The substitution of thalidomide in favor of lenalidomide in the 
maintenance phase of TT3b was done to mitigate the common toxicity of peripheral 
neuropathy associated with long-term exposure to thalidomide. Although there a minor 
protocol differences in TT3a/b, the pooled analysis of TT3a/b results were accepted in 
peer-reviewed journal Blood, in keeping with the confirmatory intent and design of TT3b 
(Nair et al., 2010). 
TT3 Entry Criteria 
All participants in the TT3 trials were treated at MIRT, were recruited and 
screened for study participation by MIRT physicians and research staff. The TT3 trials 
were posted on the publically available clinical trial registries, including 
http://www.clinicaltrials.gov. All patients enrolled on TT3 were required to provide 
written, informed consent to participate in the research protocol. Participants were 
required to have had completed all baseline studies to determine trial eligibility within 35 
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days of study registration, with the exception of a skeletal survey that must have been 
completed 90 days prior to registration. Additional study entry criteria included: 
• Patients must have had NDxMM, symptomatic MM requiring therapy 
according to the CRAB criteria (Kyle et al., 2003); 
• Protein criteria must have been present (quantifiable M-component of IgG, IgA, 
IgD, IgE and/or urinary κ or λ light chains, Bence-Jones protein, or free κ/λ light 
chains.  Non-secretory MM patients were eligible to participate if they have > 
20% plasmacyotis, or >3 focal lesions on MRI; 
• Patients may not have received more than one cycle of prior chemotherapy for 
MM; 
• Patients must have been ≤ 75 years at protocol registration; 
• Cardiac ejection fraction by ECHO or MUGA ≥ 40% performed within 60 days 
prior to registration; 
• Patients must have adequate pulmonary function with PFT’s ≥ 50% of predicted 
within 60 days prior to registration; 
• Performance status 0-2 based on the SWOG criteria; performance status of 3-4 
was permitted if attributable only to bone pain; 
• Patients must have been willing and able to comply with study procedures, 
including contraception. 
TT3 Exclusion Criteria 
Patients were excluded from participation in the TT3 protocols if any of the 
following conditions were present: 
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• Platelet count < 30 x 109/L, unless myeloma-related;   
• Grade > 2 peripheral neuropathy;   
• Hypersensitivity to bortezomib, boron, or mannitol;  
• Uncontrolled diabetes;  
• Recent (< 6 months of study registration) myocardial infarction, unstable angina, 
difficult to control congestive heart failure, uncontrolled hypertension, or difficult 
to control cardiac arrhythmias;   
• Evidence of chronic obstructive or chronic restrictive pulmonary disease;  
• light chain deposition disease or serum creatinine > 3 mg/dl;   
• prior malignancy, except for adequately treated basal cell or squamous cell skin 
cancer, in situ cervical cancer, or other cancer for which the patient has not 
received treatment for one year prior to enrollment (other cancers were only 
acceptable if the patient’s life expectancy exceeded five years);   
• no significant comorbid medical conditions or uncontrolled life-threatening 
infections; and  
• pregnant or nursing status.  
In addition, women of child-bearing potential were required to have a negative pregnancy 
test documented within one week of study registration. Women and men of reproductive 
potential could not participate unless they agreed to use an effective contraceptive 
method.   
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Power Analysis 
This study was a retrospective analysis of previously collected data from the 
prospective TT3 clinical trials. A power analysis tests the probability of rejecting the null 
hypothesis when the alternative hypothesis is true. The research plan for this study relied 
on previously collected data, thus an a priori power analysis was possible. A post-hoc 
analysis was technically possible but such an analysis requires observations from analysis 
of data and is often conducted when analysis reveals a statistically insignificant result 
(Hoenig & Heisey, 2001) and was not selected for use in this trial.  
As the essential data elements required for the planned research were 
prospectively obtained and the results of proposed analysis were unknown prior to IRB 
approval, the power analysis was performed on an a priori basis. The test family of t tests 
was used to determine the power of the study, utilizing G*Power version 3.1 (Dusseldorf 
Universitat, 2014), and guided by the statistical procedures for power calculations in 
linear regression authored by the developers of G*Power (Faul, Erdfelder, Buchner, & 
Lang, 2009).Table 4 shows the results of the G*Power calculation and demonstrates that 
the study had more participants than is required to have power of .95, an error probability 
of 0.05, and test for the research question-based number of predictors. 
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Table 4 
  
G*Power Analysis Calculator (a priori) t tests - Linear Multiple Regression: Fixed 
Model, Single Regression Coefficient 
 
Parameter Calculation 
Effect size f2 0.15 
A err prob 0.05 
Power (1-β err prob) 0.95 
Number of tested predictors 2 
Noncentrality parameter δ 3.6537652 
Critical t 1.9879342 
df 86 
Total sample size 89 
Actual power 0.9508043 
 
Data Acquisition 
The study was informed by data obtained from the Multiple Myeloma Data Base 
(MMDB) at the Myeloma Institute for Research and Therapy (MIRT) located at The 
Univeristy of Arkansas for Medical Sciences (UAMS/UARK) that was collected for the 
TT3 clinical trials. Per UAMS policy, appropriately credentialed clinical research 
professionals who have completed training, utilize MIRT standard operating procedures, 
and are authorized to access the database perform data entry in MMDB. Data obtained 
from MMDB have been utilized for research purposes, have been audited by qualified 
external reviewers, has been used for publication in peer-reviewed journals, and are 
subject to UARK IRB supervision. The data to inform this trial was obtained and/or 
analyzed with IRB permission from both UARK, IRB#204088, Expires 04/02/2016 and 
Walden University, IRB # 09-17-15-0232203, expires N/A. 
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Variables 
Dependent Variables 
There were two dependent variables in this study: PFS and OS. PFS and OS are 
commonly reported in oncology based clinical trials and were both prospectively defined 
endpoints in the TT3 trial. The definitions of PFS and OS originally used in the TT3 trials 
will be used in the planned research. TT3 defined PFS as time from study registration to 
disease progression/relapse of disease or death from any cause; OS was time from study 
registration to death from any cause (Barlogie, 2003, 2006). Progression/relapse of 
disease is defined according to the Bladé/EBMT criteria. PFS and OS are measured in 
days and reported as months/years. In this study, PFS and OS were calculated from the 
day of study registration to the date of progression or death, as recorded in MMDB on the 
data cutoff day of April 30, 2015. 
Independent Variables 
There are multiple independent variables in this study: (a) subject proximity to 
MIRT based on patient zip code, (b) GEP70-defined risk status (HRMM or LRMM), (c) 
ISS stage, (d) patient gender, and (e) age ≥ 65 years. All independent variables were 
recorded upon enrollment to TT3. Patient proximity to MIRT will be calculated based on 
distance from participant U.S. zip code to MIRT. Proximity was defined as: 
• Close proximity to MIRT: A distance from a patient’s zip code of residence to 
MIRT of < 121 miles. 
• Outside close proximity to MIRT: A distance from a patient’s zip code of 
residence to MIRT of ≥ 121 miles. 
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The honest broker managing the data utilized SAS 9.3 to compute the distance 
from subject home zip code at study registration to MIRT and provided the data to the 
principal investigator.  
GEP70 status (HRMM or LRMM) is determined by gene expression profiling of 
70 genes related to MM as described by Shaughnessy and associates (2007) and 
performed at UARK on CD138+ purified plasma cells obtained from bone marrow 
biopsy. GEP70 is a validated prognostic test used to determine the risk of early 
progression in MM. 
ISS Stage (1, 2, 3) is a validated system for patient classification and risk 
stratification. The ISS stratifies patients by obtaining levels of β2-microglobulin and 
albumin obtained from serum. The ISS staging system is utilized in both clinical and 
research practice to allow comparison of patient groups in different clinical trials. 
Data Analysis Plan 
The Cox proportional hazards model was utilized to analyze the limited dataset 
for the time to event outcomes, PFS and OS, using the statistical software R (R Core 
Team, 2015) powerSurvEpi package (Qiu, Chavarro, Lazarus, Rosner, & Ma, 2012). 
Covariates were chosen and are founded in the peer-reviewed MM literature. A result is 
considered statistically significant if a p value is < .05. 
The study was expected to reject the null hypothesis in the research questions 
below: 
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Research Question 0 
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS 
in TT3? 
Null hypothesis (H00): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT. 
Research Question 1 
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS 
in TT3, when controlling for GEP70-defined risk and ISS Stage? 
Null hypothesis (H01): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk 
and ISS Stage. 
To investigate Research Question 1, a univariate Cox PH model was used to 
separately examine the potential impact of the independent variable of proximity on the 
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS 
Stage. 
Research Question 2 
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to 
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS 
Stage? 
Null hypothesis (H02): There is no statistically significant difference in PFS or OS 
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for 
GEP70-defined risk and ISS Stage. 
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To investigate Research Question 2, a Cox PH model was used to separately 
examine the potential impact of the independent variable, patient age ≥ 65, on the 
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS 
Stage.  
Research Question 3 
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT 
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage? 
Null hypothesis (H03): There is no statistically significant difference on PFS or OS 
based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. 
To investigate Research Question 3, a Cox PH model was used to separately 
examine the potential impact of the independent variable, patient gender, on the 
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS 
Stage.  
Threats to Validity 
The TT3 clinical protocols are nonrandomized Phase II, prospective clinical trials 
that evaluated PFS and OS outcomes of 480 participants who were newly diagnosed with 
MM and treated at MIRT. The TT3 trials are closed to new patient accrual but outcomes 
for patients who remain alive have been updated weekly through the data cutoff date of 
the proposed trial. Internal threats to the validity of the proposed study include a lack of 
randomization in the TT3 trial design and the passage of time between TT3a and TT3b. 
Although the TT3 trials were not randomized, the results from the trials have been 
83 
 
published in peer-reviewed journals, cited in multiple peer-reviewed articles, and the 
findings have been incorporated in the treatment of MM in the United States and 
Internationally (Anderson, 2014; Muchtar et al., 2014).  SES data were not collected from 
participants on TT3. 
The criteria used to determine disease progression were subject to human 
interpretation but the interpretations were guided by laboratory information that is 
deemed to be highly accurate as the data were originated in a CLIA certified centralized 
pathology department at the University of Arkansas for Medical Sciences. External 
threats to validity of this study include the potential that patients enrolled on the TT3 
protocol were not representative of the general NDxMM population. Objective entry and 
exclusionary criteria for study enrollment guided subject eligibility but it is recognized 
that these results originate from a single center. 
Ethical Procedures 
This study is a review of secondary data that was determined to impose minimal 
risk to patients and was granted a waiver of informed consent and approved by the 
UARK IRB on April 3, 2015 as noted in the approval IRB approval letter (UARK IRB 
Approval #204088) (Appendix H). The UARK IRB approved amendment 1 to UARK 
2015-06 on May 12, 2015 (Appendix I).  The UARK protocol review and motoring 
committee (PRMC) acknowledged the study on April 15, 2015 (Appendix J). A letter of 
cooperation from MIRT/UARK is noted in Appendix L. The UARK IRB committee 
chairperson acknowledged the lack of need for a data use agreement (Appendix K) for 
the PI to utilize UARK 2015-06 as the data source for this study. The TT3 protocols were 
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conducted in compliance with institutional, state and federal guidance and were 
performed in accordance with the Declaration of Helsinki, subject to external audit and 
oversight by an independent Data Safety Monitoring Board (Nair et al., 2010). The data 
to inform this study were originally collected for research and clinical purposes, during 
which all participants provided written informed consent prior to TT3 enrollment.  
The study protocol mandated the use of an honest broker to prepare the data for 
submission to the PI. The honest broker was an authorized data manger from UARK who 
was responsible to remove all personally identifiable information from requested data 
sets subject to UARK IRB review and approval. The honest broker removed all 
personally identifiable data from the limited dataset and replaced study participant name 
coded in MMDB as PatID with an additionally encrypted coded number named Codeid. 
The PI will never possess or have access to the encryption key, thereby ensuring that 
personally identifiable information was protected.  
The honest broker verified that the data was retrieved from MMDB, coded 
accurately and provided a de-identified, limited data set to the PI in a Microsoft Excel 
spreadsheet. The data cut-off date of the study was April 30, 2015. The electronic limited 
dataset is stored on a password-protected computer. 
The study was also subject to Walden University IRB approval and data analysis 
did not occur until authorized by the Walden University IRB (Approval # 09-17-15-
0232203; Appendix M). The only risk to participants is the potential for a loss of privacy. 
To minimize the risk to participants, the study was conducted utilizing a limited dataset 
that contained no personally identifiable information.  
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The PI further completed training on protection of human patients in Biomedical 
Research via the Collaborative Institutional Training Initiative (CITI) program and the 
National Institutes of Health Office of Extramural Research training course Protecting 
Human Research Participants. 
No contact with any study participant was anticipated or occurred during this 
study. In the event of the loss of the limited dataset or inadvertent loss of confidentiality 
of any subject, the event will be reported to the IRB of both UARK and Walden 
University. The data will be kept in accordance with UARK IRB policy and destroyed in 
5 years from IRB approval. 
Data Dissemination 
The limited dataset was not being shared with any nonUARK IRB authorized 
individual or entity. It is anticipated that the research findings from this dissertation will 
be presented publically in aggregate form, but no personally identifiable information will 
ever be disclosed. Consistent with Walden University’s commitment to social change, the 
findings from this study will be shared with clinicians and health policy leaders. 
Summary and Transition 
Chapter 3 described the methodology of this retrospectively based, quantitative 
analysis of survival outcomes of patients treated on the TT3 protocols for NDxMM. The 
research design selected was utilized to determine if proximity to MIRT impacted PFS or 
OS when controlling for known risk factors associated with MM. The sample population 
selected is comprised from all patients treated on TT3 who consented to research and 
treatment and is believed to be representative of NDxMM patients treated at an academic 
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medical center. The use of the Cox PH model is accepted as an appropriate statistical tool 
to measure survival outcome in cancer trials and the data to inform the trial was obtained 
from clinical and research records obtained with UARK IRB approval. The research 
questions originated from a detailed literature review and variables chosen are accepted 
in the peer-reviewed literature. The data collected from subjects treated on TT3 has been 
presented publically in peer-reviewed journals and has been audited for quality by 
qualified investigators from the U.S. Food and Drug Administration and NCI supported 
investigators. UARK IRB review, monitoring and evaluation of study procedures by the 
U.S. Food and Drug Administration ensured protection of the rights of human subjects.  
This study was reviewed and approved by the appropriate IRB’s from Walden 
University and UARK. The data to inform the study was obtained by an authorized 
honest broker at UARK and consisted as a limited data set, void of personally identifiable 
information. The research methodology evaluated the limited data set to determine PFS 
and OS outcomes of patients treated on TT3 to determine if patient proximity to MIRT 
impacted outcome when other known risk factors are controlled.  
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Chapter 4: Results  
Introduction 
The purpose of this quantitative study of 480 clinical trial participants was to 
investigate the impact of patient distance from the site of care on survival outcomes for 
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. The study 
hypotheses suggested that there was a difference in progression free survival (PFS) and 
overall survival (OS)  due to logistical or patient care challenges in both planned and 
nonscheduled visits (owing to complications attributable to the disease or treatment 
related toxicities). This chapter will include a description of the data collected and the 
methodology for collection.  Any deviation from the data collection or analysis described 
in Chapter 3 will be documented. Baseline descriptive participant characteristics and 
statistical analysis for each unique research question are presented. 
Data Collection 
This retrospective study utilized secondary data obtained from the Total Therapy 
3 clinical trials at the Myeloma Institute for Research and Therapy at the University of 
Arkansas for Medical Sciences (UAMS/UARK). All clinical and geographic information 
necessary to conduct this study was obtained prospectively and recorded in the MMDB. 
The participants’ geographic locations were reported at the zip code level, but not 
analyzed as a potential variable to impact PFS and OS in Total Therapy 3 protocols. This 
study evaluated the dependent variables of PFS and OS outcome for all 303 patients 
enrolled on Total Therapy 3a from February 2004 – July 2006 and the 177 patients 
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enrolled on Total Therapy 3b from November 2006 – September 2008. Unless a study 
participant had withdrawn consent, was lost to follow up, or died, researchers from the 
Myeloma Institute for Research and Therapy actively followed them for disease 
progression and outcome. Protocol specific procedures mandated that a bone marrow 
specimen was to be obtained for the purpose GEP, serum chemistry studies obtained from 
peripheral blood, and that imaging studies be performed. Measurement of baseline serum 
albumin and β-2 microglobulin were used to determine the ISS Stage (Appendix C). 
Information obtained for this study included a “Codeid” as a unique participant identifier, 
gender (male or female), ethnicity, protocol (TT3a or TT3b) enrollment, GEP70 Status 
(low or high risk), date enrolled on protocol, age at baseline (protocol enrollment), date 
of progression, date of death, date of last contact, reason for removal from protocol, 
distance from MIRT and ISS Stage. Table 5 presents baseline demographic information 
of study participants at protocol enrollment. 
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Table 5 
    
Descriptive Statistics at Study Enrollment 
    
Variable n N % 
Distance < 121 miles 72 480 15 
Age >= 65 yrs. 130 480 27 
Female 179 480 37 
at least 1 cycle of prior therapy 51 480 11 
ISS Stage 1 196 478 41 
ISS Stage 2 166 478 35 
ISS Stage 3 116 478 24 
GEP-70 High Risk 80 469 17 
Asian 5 480 1 
Black 33 480 7 
Native American 1 480 0 
Pacific Islander 1 480 0 
White 428 480 89 
Refused/Blank 12 480 3 
Note. Baseline GEP70 results were not available for 11 participants.  
The variance between all enrolled subjects in Total Therapy 3 and baseline 
characteristics reported in this study is the lack of available GEP70 and/or the necessary 
information to assign an ISS Stage within the time allowed in the original protocols. The 
most common reason for the lack of GEP information was failed bone marrow sampling 
or insufficient quality of the sample. In the event of a failed sample, a repeat bone 
marrow sample was sought. In total, of the 480 participants enrolled on Total Therapy 3, 
11 participants were not assigned a baseline GEP70 risk status. This study excluded 
participants whose records did not have both a GEP70 risk status assignment and ISS 
Stage within the time period required by the original study protocols. In this study, 469 
participants are considered evaluable. 
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The population in this study was generally representative of the population of 
those persons with NDxMM based on the standardized criteria established by the DS. 
The proportion of male to female participants was consistent with data reported in the 
SEER database and by the NCCN (Anderson, 2014; National Cancer Institute, 2015c). 
GEP information was not available for the majority of persons diagnosed with MM as the 
test is considered investigational (Anderson, 2014). The median age of study participants 
was 59 years (30-74) and the median followup was 8.9 years later. 
The original ISS data were obtained from 10,750 untreated patients with NDxMM 
(Greipp et al., 2005). The TT3 trials have a higher proportion of patients with Stage 1 and 
2 disease when compared to the original ISS data; however, patients may have received 
one line of treatment prior to study enrollment if urgent therapy was required (Barlogie, 
2003, 2006). A rapid change in ISS stage is biologically and therapeutically feasible with 
the administration of one cycle of anti-MM treatment. Table 6 presents the distribution of 
ISS Stage at diagnosis between the original ISS report and the 469 evaluable participants 
in this study. 
 
Table 6   
   
ISS Stage Distribution at Diagnosis 
 
ISS Stage ISS Participants 
% 
Total Therapy 3 
% 
Stage 1 28 41 
Stage 2 33 35 
Stage 3 39 24 
Note.   Adapted from “International staging system for multiple myeloma” by Greipp, P. 
R., San Miguel, J., Durie, B., Crowley, J. J., Barlogie, B., Bladé, J., … Kyle, R. 
(2005).  Journal of Clinical Oncology, 23(15), 3412–3420. Copyright, The 
American Society of Clinical Oncology. 
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A Cox regression analysis was performed to determine the hazard ratio (HR) for risk of 
PFS or OS based on close proximity to MIRT. Additional Cox regression was performed 
to determine the HR for PFS and OS based on distance and covariates that are known to 
influence survival, including GEP-70 risk status, age ≥ 65 years, and gender. 
The Cox PH model is generally used to provide an estimate of HR and the bounding 
confidence interval and is one of the most commonly used models in outcome research 
(Spruance, Reid, Grace, & Samore, 2004) as it is applicable to many disease states. 
When assigned to outcomes research, a HR <1.0 indicates that the group or 
research variable of interest, is less likely to experience the event of interest. An HR = 1.0 
indicates that the groups have an equal risk of the event of interest. A HR > 1.0 indicates 
that the group or research variable of interest, is more likely to experience the event of 
interest. In this study, participants were stratified by distance traveled to MIRT, the 
groups are defined as those who live in either close proximity to MIRT (<121 miles from 
MIRT) or those not in close proximity to MIRT (≥ 121 miles). 
Research Question 0  
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS 
in TT3? 
Null hypothesis (H00): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT. 
Alternative Hypothesis (HA0): There is a statistically significant difference to PFS or 
OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined 
risk and ISS Stage. 
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Research Question 0: PFS Result 
480 participants were evaluated for PFS outcome without regard to GEP-70 defined 
risk and ISS Stage. Close proximity to MIRT was associated with a statistically 
significant shorter PFS result HR 1.73, 95% CI [1.22 - 2.46], p = .001. The Wald statistic 
showed that the overall effect of close proximity to MIRT on PFS in TT3 was significant, 
p = 0.001. The hazard ratio obtained for this result was 1.73, indicating close proximity to 
MIRT was associated with increased risk of shorter PFS compared to those outside of 
close proximity. 
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Figure 3. Research Question 0 PFS results. 
 
Research Question 0: OS Result 
 
480 participants were evaluated for OS outcome without regard to GEP-70 defined 
risk and ISS Stage. Close proximity to MIRT was associated with a statistically 
significant shorter OS result HR 1.73, 95% CI [1.22 - 2.45], p = .002. The Wald statistic 
showed that the overall effect of close proximity to MIRT on PFS in TT3 was significant, 
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p = 0.002. The hazard ratio obtained for this result was 1.73, indicating close proximity to 
MIRT was associated with increased risk of shorter OS compared to those outside of 
close proximity. 
 
 
Figure 4. Research Question 0 OS results.  
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Table 7       
      
Regression Results for Research Question 0 
      
Variable PFS/OS HR SE HR z p 
Distance (<121 miles) PFS 1.73 .177 3.11 .001 
Distance (<121 miles) OS 1.73 .177 3.08 .002 
 
Research Question 0 results indicate that distance from MIRT was associated with 
statistically significant differences in PFS and OS outcome. Research Questions 1-3 
tested the hypothesis when controlling for established factors associated with MM, 
including GEP-70 status, ISS Stage, and gender. 
Research Question 1 
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS 
in TT3, when controlling for GEP70-defined risk and ISS Stage? 
Null hypothesis (H01): There is no statistically significant difference to PFS or OS 
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk 
and ISS Stage. 
Alternative Hypothesis (HA1): There is a statistically significant difference to PFS 
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined 
risk and ISS Stage. 
Research Question 1: PFS Result 
 
469 of 480 participants had baseline GEP and ISS Stage results. Close proximity to 
MIRT was associated with a statistically significant shorter PFS result HR 1.67, 95% CI 
[1.17 - 2.38], p = .004 in TT3 after controlling for the effect of GEP70-defined risk and 
ISS Stage. The Wald statistic showed that the overall effect of close proximity to MIRT 
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on PFS in TT3 was significant, p = 0.000. The hazard ratio obtained for this result was 
1.67, indicating close proximity to MIRT was associated with increased risk of shorter 
PFS compared to those outside of close proximity when controlling for GEP70-defined 
risk and ISS Stage. The null hypothesis is rejected. 
Research Question 1: OS Result 
 
469 of 480 participants had baseline GEP and ISS Stage results. Close proximity to 
MIRT was associated with a statistically significant shorter OS result HR 1.67, 95% CI 
[1.17 - 2.39], p = .004 in TT3 after controlling for the effect of GEP70-defined risk and 
ISS Stage. The Wald statistic showed that the overall effect of close proximity to MIRT 
on PFS in TT3 was significant, p = 0.000. The hazard ratio obtained for this result was 
1.67, indicating close proximity to MIRT was associated with increased risk of shorter 
PFS compared to those outside of close proximity when controlling for GEP70-defined 
risk and ISS Stage. The null hypothesis is rejected. 
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Figure 5. Research Question 1 OS results. Note. Figure abbreviations, HR = GEP-70 
High Risk; LR = GEP-70 Low Risk 
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Table 8 
      
Regression Results for Research Question 1 
      
Variable PFS/OS HR SE HR z p 
Distance (<121 miles) PFS 1.67 .181 2.83 .004 
Distance (<121 miles) OS 1.67 .181 2.85 .004 
 
The results of the analysis compel rejection of the null hypothesis for research 
question one that there is no statistically significant difference on PFS or OS based on a 
patient’s close proximity to MIRT, when controlling for GEP70-defined risk and ISS 
Stage. Results support the alternative hypothesis that there is a statistically significant 
difference on PFS or OS based on a patient’s close proximity to MIRT, when controlling 
for GEP70-defined risk and ISS Stage. 
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Research Question 2 
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to 
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS 
Stage? 
Null hypothesis (H02): There is no statistically significant difference in PFS or OS 
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for 
GEP70-defined risk and ISS Stage. 
Alternative Hypothesis (HA2): There is a statistically significant difference in PFS 
or OS based on a patient age ≥ 65 years and close proximity to MIRT after controlling for 
GEP70-defined risk and ISS Stage. 
Research Question 2: PFS Result 
One hundred and thirty (n=130) of 480 participants were ≥ 65 years at study 
enrollment; 126 of 130 participants ≥ 65 years had both baseline GEP and ISS Stage 
results available and were evaluated in this research question. Patient age ≥ 65 years and 
close proximity to MIRT was associated with a statistically significant shorter PFS result 
HR 1.88, 95% CI [1.07 - 3.28], p = .026 in TT3 after controlling for the effect of GEP70-
defined risk and ISS Stage. The Wald statistic showed that the overall effect of close 
proximity to MIRT on PFS in TT3 was significant, p = .0000. The hazard ratio obtained 
for this result was 1.88, indicating close proximity to MIRT was associated with 
increased risk of shorter PFS compared to those outside of close proximity when 
controlling for GEP70-defined risk and ISS Stage. The null hypothesis is rejected. 
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Research Question 2: OS Result 
One hundred and thirty (n=130) of 480 participants were ≥ 65 years at study 
enrollment; 126 of 130 participants ≥ 65 years had both baseline GEP and ISS Stage 
results available and evaluated in this research question. Patient age ≥ 65 years and close 
proximity to MIRT was associated with a statistically significant shorter PFS result HR 
1.75, 95% CI [1.00 – 3.06], p = .049 in TT3 after controlling for the effect of GEP70-
defined risk and ISS Stage. The Wald statistic showed that the overall effect of close 
proximity to MIRT on PFS in TT3 was significant, p = .0000. The hazard ratio obtained 
for this result was 1.75, indicating close proximity to MIRT was associated with 
increased risk of shorter OS compared to those outside of close proximity when 
controlling for GEP70-defined risk and ISS Stage. The null hypothesis is rejected. 
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Figure 6. Research Question 2 OS results. HR = GEP-70 High Risk; LR = GEP-70 Low 
Risk 
 
Table 9      
      
Regression Results for Research Question 2 
      
Variable PFS/OS HR SE HR z p 
Distance (<121 miles) PFS 1.88 .284 2.21 .026 
Distance (<121 miles) OS 1.75 .285 1.96 .049 
 
Years from Enrollment
Pe
rc
en
t S
ur
viv
ing
20%
40%
60%
80%
100%
0 2 4 6 8 10 12
Events / N 5−Year Survival
>= 121 miles : LR  33 / 82 79.2 ( 70.8 , 88.5 )
>= 121 miles : HR  16 / 18 33.3 ( 17.3 , 64.1 )
< 121 miles : LR  15 / 23 60.9 ( 43.9 , 84.5 )
< 121 miles : HR  3 / 3 0.0 ( NA , NA )
Logrank p−Value = 5.967e−09
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The results of the analysis compel rejection of the null hypothesis for research 
question two that there is no statistically significant difference in PFS or OS based on a 
patient age ≥ 65 years and close proximity to MIRT after controlling for GEP70-defined 
risk and ISS Stage. Results support the alternative hypothesis that there is a statistically 
significant difference in PFS or OS based on a patient age ≥ 65 years and close proximity 
to MIRT after controlling for GEP70-defined risk and ISS Stage. 
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Research Question 3 
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT 
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage? 
 
Null hypothesis (H03): There is no statistically significant difference on PFS or OS 
based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. 
Alternative Hypothesis (HA3): There is a statistically significant difference on PFS 
or OS based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. 
Research Question 3: PFS Result 
There were 179 females and 301 males in the TT3 clinical trials. Baseline GEP 
results were available for 175 females and 294 males. Gender and GEP baseline 
information was available for 469 of 480 participants. Patient gender and close proximity 
to MIRT did not significantly impact PFS in TT3, HR 1.01, 95% CI [.75 – 1.35], p = .94. 
The hazard ratio obtained for this result was 1.01, indicating close proximity to MIRT 
was not associated with increased risk of shorter PFS compared to those outside of close 
proximity, when controlling for GEP70-defined risk and ISS Stage. The null hypothesis 
cannot be rejected. 
Research Question 3: OS Result 
There were 179 females and 301 males in the TT3 clinical trials. Baseline GEP 
results were available for 175 females and 294 males. Gender and GEP baseline 
information was available for 469 of 480 participants. Patient gender and close proximity 
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to MIRT did not significantly impact PFS in TT3, HR .99, 95% CI [.73 – 1.33], p = .96. 
The hazard ratio obtained for this result was .99, indicating close proximity to MIRT was 
not associated with increased risk of shorter PFS compared to those outside of close 
proximity when controlling for GEP70-defined risk and ISS Stage. The null hypothesis 
cannot be rejected. 
 
Figure 7. Research Question 3 OS results. HR = GEP-70 High Risk; LR = GEP-70 Low 
Risk. 
 
Table 10 
     
      
Regression Results for Research Question 3 
      
Variable PFS/OS HR SE HR z p 
Distance (<121 miles) PFS 1.01 .150 .075 .940 
Distance (<121 miles) OS .99 .150 -0.05 .960 
 
Years from Enrollment
Pe
rc
en
t S
ur
viv
ing
20%
40%
60%
80%
100%
0 2 4 6 8 10 12
Events / N 5−Year Survival
>= 121 miles : LR  64 / 215 84.6 ( 79.9 , 89.6 )
>= 121 miles : HR  30 / 37 37.8 ( 25.0 , 57.2 )
< 121 miles : LR  18 / 37 67.6 ( 54.0 , 84.5 )
< 121 miles : HR  4 / 5 40.0 ( 13.7 , 100.0 )
Logrank p−Value = 9.497e−16
Years from Enrollment
Pe
rc
en
t S
ur
viv
ing
20%
40%
60%
80%
100%
0 2 4 6 8 10 12
Events / N 5−Year Survival
>= 121 miles : LR  32 / 115 80.9 ( 74.0 , 88.4 )
>= 121 miles : HR  24 / 32 34.4 ( 21.3 , 55.5 )
< 121 miles : LR  12 / 22 68.2 ( 51.3 , 90.7 )
< 121 miles : HR  5 / 6 16.7 ( 2.8 , 99.7 )
Logrank p−Value = 1.331e−08
Males Females 
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The results of the model did not compel rejection of the null hypothesis for 
research question three that there is no statistically significant difference on PFS or OS 
based on patient gender and close proximity to MIRT after controlling for GEP70-
defined risk and ISS Stage in TT3. Results demonstrated that close proximity to MIRT 
had a significant impact on both PFS and OS after controlling for GEP70-defined risk 
and ISS Stage in TT3, while gender did not have a statistically significant impact on PFS 
or OS. 
Summary  
This study sought to determine if patient travel distance to MIRT impacted PFS or 
OS outcome in the TT3 trials for NDxMM.  Patient travel distance was categorized as 
either in close proximity, defined as residence in a zip code that is <120 miles from 
MIRT, whereas those outside of proximity to MIRT live in a zip code ≥ miles from 
MIRT. The results of this study indicate that close proximity to MIRT is associated with 
statistically significant differences in PFS and OS which are associated with shorter PFS 
and OS. ISS Stage and GEP-70 defined risk are known to influence PFS and OS in 
NDxMM. This study determined that patient distance traveled in TT3 does impact PFS 
and OS, this determination is statistically significant in a Cox PH model where distance 
traveled, ISS Stage, and GEP-70 risk stratification are both included and controlled for. 
The variables of age ≥ 65 and gender were also evaluated in the Cox PH model. When 
controlling for ISS Stage and GEP-70 risk stratification, age ≥ 65 was statistically 
significant as a negative modifier on PFS and OS, but gender was not associated with a 
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statistically significant risk. The null hypothesis was rejected in the first two research 
questions in this study, but cannot be rejected in the third question.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this quantitative study of 480 clinical trial participants was to 
investigate the impact of patient distance from the site of care on survival outcomes for 
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. Current 
diagnostic and prognostic schemas do not incorporate patient distance traveled to the site 
of care for MM despite evidence that it may impact PFS and OS. This study addressed 
this gap by retrospectively examining prospectively collected data including distance 
from the patient’s home to MIRT, ISS Stage, age, GEP-70 risk stratification to determine 
if near proximity (distance <120 miles from MIRT) impacted PFS or OS compared to a 
proximity ≥ 121 miles.  
The results of this study indicate that patients in close proximity to MIRT have an 
increased hazard of progression and death. The conclusions that close proximity to MIRT 
is associated with an increased hazard of early progression and death was determined to 
be statistically significant; this conclusion was also determined to be valid when known 
predictors of risk, including ISS Stage, GEP-70 based risk, and age ≥ 65 were introduced 
into the Cox PH model. Gender was not determined to be associated with an increased 
risk of progression or death. 
Interpretation of the Findings 
Previous studies examining the potential of patient distance traveled to impact 
PFS or OS have yielded inconsistent findings and have not been tested in a large sample 
after the introduction of novel therapy followed by autologous stem cell transplant 
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(ASCT). The results of this study are consistent with the major findings of Lenhard and 
associates (1987) and Lipe et al., 2012, such that patient distance traveled did impact 
overall survival (OS). The baseline demographic characteristics in this trial were 
consistent with previously reported studies of NDxMM. In contrast to the majority of the 
existing literature investigating the role of distance in PFS and OS in NDxMM, this study 
used a singular treatment regimen and strict entry criteria for study participation. This is 
the largest currently reported study investigating the role of patient distance traveled to 
impact PFS and OS outcome where all patients received combination novel therapy 
induction, tandem ASCT, and three year, three drug maintenance therapy.  
Several additional facets make this study unique in its contribution and expansion 
of the literature. The NCCN recommends that NDxMM patients who are eligible for 
ASCT, be treated with novel drug based induction therapy, ASCT, and maintenance 
therapy; this study represents long-term follow up of patients treated in a similar fashion 
to current NCCN recommendations. This study is also unique in that it included both the 
ISS Staging System, which is available in most clinical practices and the research based 
GEP-70 risk based stratification of NDxMM. The application of both routine and 
investigational risk stratification schemas in the analysis of distance as a risk factor in 
NDxMM, allows for the application of this information in both academic and community 
based practice settings. This information is of interest to the broad community of health 
care providers who treat MM as this study analyzed novel therapy in combination with 
classic chemotherapy and utilized two ASCT procedures and planned multiyear 
maintenance therapy. The findings that distance from the site of care impacts PFS and OS 
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for those undergoing therapy for multiple myeloma should be a clinical concern and 
variable to consider at diagnosis. 
The findings from this study are confounded by the lack of SES data collection 
and analysis in the original study from which data were obtained. An assumption of this 
trial is that participants who lived ≥ 121 miles from MIRT had the financial resources, 
physical ability, and desire to travel to Arkansas for treatment. Those without the ability 
to travel to Arkansas/MIRT for treatment could not have been enrolled on the TT3 
protocols; persons who lived < 121 miles from MIRT, by definition, are residents of the 
State of Arkansas and may have been eligible for TT3 participation, even if they were 
financially indigent. Placed in the historical context of MM treatment in 2003, the use of 
novel drug combination chemotherapy in the NDxMM setting, followed by tandem 
ASCT, and three year, three drug maintenance therapy was not routine, was 
investigational, and not the standard of care. The choice to travel to MIRT from outside 
of the State of Arkansas and participate in TT3 implies higher health literacy and SES 
status. 
Theoretical Framework of the Study 
Andersen’s behavioral model of health services (BMH) use (1995) serves as the 
theoretical framework of this study. The BMH has been widely utilized as a framework 
for health services and outcomes and has undergone revision since its introduction in the 
1960’s to be applicable to individual decision making with respect to healthcare services 
use. The application of the BMH to the this study is predicated on the hypothesis that 
patient distance traveled to the site of care for MM may be impactful on PFS and OS and 
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is consistent with Andersen’s assertion that distance and availability of healthcare 
services are key factors in an individual’s choice to access the healthcare system. 
Limitations of the Study 
This study is a retrospective analysis of secondary data collected from TT3. 
Although the data analyzed in this study did not originate from a randomized clinical trial 
investigating the research questions in the study. This study originated from data 
collected at a single center, which may limit the applicability of the results. 
Socioeconomic Status (SES) status is known to impact PFS and OS in cancer and 
the results from this study are likely confounded by the lack of SES data. SES data was 
not collected or analyzed in this study. Furthermore, gross measures of SES associated 
with zip code of residence or “cash on hand” may not adequately inform the likelihood of 
drug regimen persistence, compliance to treatment plans/protocol. This study is unique in 
that the median follow up, as of the date of data cut-off is nearly 9 years. The relatively 
large sample size of this study combined with the consistency of the baseline 
demographics of the population implies that this study is trustworthy, valid, and 
repeatable.  
Recommendations 
The results from this trial indicate that distance should be examined in future 
studies as an impactful variable on progression and death in NDxMM. Results from this 
trial should be used as a proof of concept, or as a “training set” to retrospectively analyze 
the Total Therapy 4-6 clinical trials. If future analysis of TT4-6 confirms these findings, 
the prospective collection of distance and SES information should be included on future 
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clinical trials at MIRT. One confirmed in multiple retrospective trials and one prospective 
trial, the information should be made available to professional organizations involved in 
NDxMM disease prognostication schemas, including the International Myeloma Working 
Group, NCCN, and the American Society of Hematology. Furthermore, the application of 
these findings to other cancer centers that collect data concerning long-term outcomes 
and have publically available data is another recommended practice. In the event that 
distance, as a prognostic variable is evaluated in a prospective clinical trial, a team of 
qualified public health practitioners, policy makers, hematologists, social workers, and 
outcome research specialists should be convened to plan an ideal data collection and 
analysis plan. 
Implications for Social Change 
This study affirms the applicability of Anderson’s (1995) model of behavioral 
health services to a relatively rare adult hematologic malignancy. Although MM is a 
relatively rare cancer, findings from this study may be applied to any planned therapeutic 
regimen which incorporates ASCT. ASCT is a standard of care in many more common 
malignancies, including some lymphomas and leukemias. Distance as a prognostic 
variable may also be viewed in the context of access to healthcare.  
This study promotes positive social change by demonstrating the potential of 
patient travel distance to shorten life expectancy. It also raises additional and troubling 
questions regarding the role of SES to impact cancer survivorship. As the U.S. healthcare 
delivery system is adapting to recent legislative changes, the application of these findings 
to healthcare policy decisions regarding the ability of a person to travel outside of their 
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local health “network” to seek optimal care should be addressed. The ability of a person 
to access healthcare and experience better outcomes as a function of distance traveled for 
care or SES is a known and policy modifiable healthcare inequity. 
Conclusion 
MM is a rare malignant transformation of plasma cells that is characterized by 
bone pain, anemia, skeletal fracture, and shortened life span. Recent advances in the 
treatment of NDxMM have extended the PFS and OS for patients with the disease. 
Distance to the site of care for MM has been demonstrated to impact PFS and OS and this 
study confirms this observation in the TT3 trials for NDxMM. The TT3 trials are notable 
for the use of combination novel therapy based induction, tandem ASCT, multi-year, 
multi-drug maintenance therapy, and long-follow up. With a median of nearly 9 years of 
follow up, patient travel distance to the site of care has been shown to impact PFS and OS 
outcome, favoring those who live beyond 121 miles of MIRT. This quantitative, 
retrospective study of 480 participants with NDxMM has demonstrated that patient travel 
distance, and likely, SES is prognostic variables for survival. This study is the largest 
study reporting PFS and OS outcomes for patients who were treated for NDxMM in the 
era of novel therapy. Comparisons of survival from clinical trials which differ in design 
are not scientifically appropriate; however, it should be noted that OS reported in this 
trial exceeds published reference standards of 2003 and 2015.  
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Appendix A: EBMT Criteria 
Criteria for evaluating disease response and progression in patients with multiple 
myeloma treated by high-dose therapy and haemopoietic stem cell transplantation  
 
Adapted from Blade et al. (1998, p. 1119). 
 
Complete response (CR) requires all of the following: 
1. Absence of the original monoclonal paraprotein in serum and urine by 
immunofixation, maintained for a minimum of 6 weeks. The presence of 
oligoclonal bands consistent with oligoclonal immune reconstitution does not 
exclude CR. 
2. < 5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if 
biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it 
is not necessary to repeat the bone marrow, except in patients with nonsecretory 
myeloma where the marrow examination must be repeated after an interval of at 
least 6 weeks to confirm CR. 
3. No increase in size or number of lytic bone lesions (development of a 
compression fracture does not exclude response). 
4. Disappearance of soft tissue plasmacytomas. 
 
Patients in whom some, but not all, the criteria for CR are fulfilled are classified as 
PR, providing the remaining criteria satisfy the requirements for PR. This includes 
patients in whom routine electrophoresis is negative but in whom immunofixation has 
not been performed. 
 
Partial response (PR) requires all of the following: 
1. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for 
a minimum of 6 weeks. 
2. Reduction in 24 h urinary light chain excretion either by >90% or to <200 mg, 
maintained for a minimum of 6 weeks. 
3. For patients with nonsecretory myeloma only, >50% reduction in plasma cells in 
a bone marrow aspirate and on trephine biopsy, if biopsy is performed, 
maintained for a minimum of 6 weeks. 
4. >50% reduction in the size of soft tissue plasmacytomas (by radiography or 
clinical examination). 
5. No increase in size or number of lytic bone lesions (development of a 
compression fracture does not exclude response). 
 
Patients in whom some, but not all, the criteria for PR are fulfilled are classified as 
MR, provided the remaining criteria satisfy the requirements for MR. 
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Minimal response (MR) requires all of the following: 
1. 25–49% reduction in the level of the serum monoclonal paraprotein maintained 
for a minimum of 6 weeks. 
2. 50–89% reduction in 24 h urinary light chain excretion, which still exceeds 200 
mg/24 h, maintained for a minimum of 6 weeks. 
3. For patients with nonsecretory myeloma only, 25–49% reduction in plasma cells 
in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, 
maintained for a minimum of 6 weeks. 
4. 25–49% reduction in the size of soft tissue plasmacytomas (by radiography or 
clinical examination). 
5. No increase in the size or number of lytic bone lesions (development of a 
compression fracture does not exclude response). 
 
MR also includes patients in whom some, but not all, the criteria for PR are fulfilled, 
provided the remaining criteria satisfy the requirements for MR. 
 
No change (NC) 
1. Not meeting the criteria of either minimal response or progressive disease. 
 
Plateau 
1. Stable values (within 25% above or below value at the time response is assessed) 
maintained for at least 3 months. 
 
Time point for assessing response 
1. Response to the transplant procedure will be assessed by comparison with results 
immediately prior to conditioning. 
2. If transplant is part of a treatment programme, response to the whole treatment 
programme will be assessed by comparison with the results at the start of the 
programme. 
 
Relapse from CR requires at least one of the following: 
1. Reappearance of serum or urinary paraprotein on immunofixation or routine 
electrophoresis, confirmed by at least one further investigation and excluding 
oligoclonal immune reconstitution. 
2. ≥5% plasma cells in a bone marrow aspirate or on trephine bone biopsy. 
3. Development of new lytic bone lesions or soft tissue plasmacytomas or definite 
increase in the size of residual bone lesions (development of a compression 
fracture does not exclude continued response and may not indicate progression). 
4. Development of hypercalcaemia (corrected serum calcium >11·5 mg/dl or 2·8 
mmol/l) not attributable to any other cause. 
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Progressive disease (for patients not in CR) requires one or more of the following: 
 
1. >25% increase in the level of the serum monoclonal paraprotein, which must also 
be an absolute increase of at least 5 g/l and confirmed by at least one repeated 
investigation. 
2. >25% increase in the 24 h urinary light chain excretion excretion, which must also 
be an absolute increase of at least 200 mg/24 h and confirmed by at least one 
repeated investigation. 
3. >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, 
which must also be an absolute increase of at least 10%. 
4. Definite increase in the size of existing bone lesions or soft tissue plasmacytomas. 
5. Development of new bone lesions or soft tissue plasmacytomas (development of a 
compression fracture does not exclude continued response and may not indicate 
progression). 
6. Development of hypercalcaemia (corrected serum calcium >11·5 mg/dl or 2·8 
mmol/l) not attributable to any other cause. 
 
 
147 
 
Appendix B: Durie-Salmon Criteria 
(Adapted from Durie & Salmon (1975) 
 
Stage I 
 
All of the following: 
§ Hb > 10g/dL  
§ normal calcium  
§ Skeletal survey: normal or single plasmacytoma or 
osteoporosis  
§ Serum paraprotein level < 5 g/dL if IgG, < 3 g/dL if IgA  
§ Urinary light chain excretion < 4 g/24h  
 
Stage II 
 Fulfilling the criteria of neither I nor III 
Stage III 
 
One or more: 
§ Hb < 8.5g/dL  
§ high calcium > 12 mg/dL  
§ Skeletal survey: Three or more lytic bone lesions  
§ Serum paraprotein > 7g/dL if IgG, > 5 g/dL if IgA  
§ Urinary light chain excretion > 12g/24h  
 
Sub-
classification 
 
A = Relatively normal renal function (serum creatinine value < 2.0 
mg/100 ml) 
B = Abnormal renal function (serum creatinine value > 2.0 mg/100 ml) 
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Appendix C: International Staging System (ISS) 
International Staging System (Greipp, San Miguel, Durie, Crowley, Barlogie, 
Bladé, Boccadoro, Child, Avet-Loiseau, & Kyle, 2005) 
 
International Staging System 
Stage Criteria Median Survival 
(months) 
I Serum β2-microglobulin < 
3.5mg/L 
Serum Albumin > 3.5 g/dL 
 
62 
II Not stage I or III 44 
 
III Serum β2-microglobulin > 
5.5 mg/L 
29 
 
*There are two categories for stage II: serum β2-microglobulin < 3.5 mg/L but serum 
albumin < 3.5 g/dL; or serum β2-microglobulin 3.5 to < 5.5 mg/L irrespective of the serum 
albumin level. 
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Appendix D: CRAB Criteria 
Criteria for the classification of monoclonal gammopathies, multiple myeloma and 
related disorders: a report of the International Myeloma Working Group 
 
Adapted from Kyle et al. (2003). 
 
Diagnosis Diagnostic Criteria: All Three Required 
Symptomatic Multiple Myelomaa Monoclonal plasma cells in the bone 
marrow ≥ 10% and/or presence of a 
biopsy-proven plasmacytoma 
 
Monoclonal protein present in the serum 
and/or urineb 
 
Myeloma-related organ dysfunction (≥ 1)c 
 
[C] Calcium elevation in the blood (serum 
calcium > 10.5 mg/l or upper limit of 
normal)  
 
[R] Renal insufficiency (serum creatinine > 
2 mg per 100 ml)  
 
[A] Anemia (hemoglobin < 10 g per 100 
ml or 2 g < normal) 
 
[B] Lytic bone lesions or osteoporosisd 
 
a These criteria identify Stage IB and Stages II and III A/B myeloma by Durie/Salmon 
stage. Stage IA becomes smoldering or indolent myeloma.  
b If no monoclonal protein is detected (nonsecretory disease), then ≥ 30% monoclonal 
bone marrow plasma cells and/or a biopsy-proven plasmacytoma required.  
c A variety of other types of end-organ dysfunctions can occasionally occur and lead to a 
need for therapy. Such dysfunction is sufficient to support classification as myeloma if 
proven to be myeloma related.  
d If a solitary (biopsy-proven) plasmacytoma or osteoporosis alone (without fractures) is 
the sole defining criteria, then ≥ 30% plasma cells are required in the bone marrow. 
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Appendix E: Total Therapy 3a Treatment Plan 
 
Induction I 
VTD-PACE #1 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 4 – 7 
D 40 mg/d           d 4 – 7  
P 10 mg/m2   d 4 – 7 CI 
A 10 mg/m2  d 4 – 7 CI 
C 400 mg/m2  d 4 – 7 CI 
E 40 mg/m2   d 4 – 7 CI 
  
PBSC collection > 20 x 106 CD34/kg  
Bridging THAL 50 mg-DEX 20mg 
 
Induction 2 
 
[6 weeks to 8 weeks post Induction 1] 
VTD-PACE #2 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 10 mg/m2   d 1 – 4 CI 
A 10 mg/m2  d 1 – 4 CI 
C 400 mg/m2  d 1 – 4 CI 
E 40 mg/m2   d 1 – 4 CI 
Bridging THAL 50 mg-DEX 20mg 
Transplant 1 
 
[3 weeks to 12 weeks post Induction 2] 
MEL 200 
M 200 mg/m2  d -1  
D 40 mg/d  d -2 to +1  
 
Bridging THAL 100 mg-DEX 20mg 
Transplant 2 
 
[8 weeks to 6 months post Transplant 1] 
MEL 200 
M 200 mg/m2  d -1  
D 40 mg/d  d -2 to +1  
 
Bridging THAL 100 mg-DEX 20mg 
Consolidation 1 
 
[6 weeks to 6 months post Transplant 2] 
VTD-PACE 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 7.5 mg/m2   d 1 – 4 CI 
A 7.5 mg/m2  d 1 – 4 CI 
C 300 mg/m2  d 1 – 4 CI 
E 30 mg/m2   d 1 – 4 CI 
Bridging THAL 100 mg-DEX 20mg 
Consolidation 2 
 
[8 weeks to 12 weeks post Consolidation 1] 
VTD-PACE 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 7.5 mg/m2   d 1 – 4 CI 
A 7.5 mg/m2  d 1 – 4 CI 
C 300 mg/m2  d 1 – 4 CI 
E 30 mg/m2   d 1 – 4 CI 
Maintenance Year 1: 
 
[ 4 weeks to 4 months post Consolidation 2]  
 
 
 
 
Maintenance Year 2-3 
Treatment for 3 years: 
VTD 
V 1.0 mg/m2/wk  d 1, 4, 8, 11 
T 100 mg/d          d 1 – 28 
D 20 mg/wk  d 1-4 and 8-11 
 
VTD weekly 
V 1.0 mg/m2/wk  d 1, 8, 15, 22 
T 100 mg/d          d 1 – 28 
D 20 mg/wk  d 1, 8, 15, 22 
Or  
TD 
T     100/mg/d              d 1-28 
D    20 mg/d               d 1-4 
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Appendix F: Total Therapy 3b Treatment Plan 
 
Induction I 
VTD-PACE #1 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 4 – 7 
D 40 mg/d           d 4 – 7  
P 10 mg/m2   d 4 – 7 CI 
A 10 mg/m2  d 4 – 7 CI 
C 400 mg/m2  d 4 – 7 CI 
E 40 mg/m2   d 4 – 7 CI 
  
PBSC collection > 20 x 106 CD34/kg  
Bridging THAL 50 mg-DEX 20mg 
 
Induction 2 
 
[6 weeks to 8 weeks post Induction 1] 
VTD-PACE #2 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 10 mg/m2   d 1 – 4 CI 
A 10 mg/m2  d 1 – 4 CI 
C 400 mg/m2  d 1 – 4 CI 
E 40 mg/m2   d 1 – 4 CI 
Bridging THAL 50 mg-DEX 20mg 
Transplant 1 
 
[3 weeks to 12 weeks post Induction 2] 
MEL 200 
M 200 mg/m2  d -1  
D 40 mg/d  d -2 to +1  
 
Bridging THAL 100 mg-DEX 20mg 
Transplant 2 
 
[8 weeks to 6 months post Transplant 1] 
MEL 200 
M 200 mg/m2  d -1  
D 40 mg/d  d -2 to +1  
 
Bridging THAL 100 mg-DEX 20mg 
Consolidation 1 
 
[6 weeks to 6 months post Transplant 2] 
VTD-PACE 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 7.5 mg/m2   d 1 – 4 CI 
A 7.5 mg/m2  d 1 – 4 CI 
C 300 mg/m2  d 1 – 4 CI 
E 30 mg/m2   d 1 – 4 CI 
Bridging THAL 100 mg-DEX 20mg 
Consolidation 2 
 
[8 weeks to 12 weeks post Consolidation 1] 
VTD-PACE 
V 1.0 mg/m2  d 1, 4, 8 and 11 
T 200 mg/d  d 1 – 4 
D 40 mg/d           d 1 – 4  
P 7.5 mg/m2   d 1 – 4 CI 
A 7.5 mg/m2  d 1 – 4 CI 
C 300 mg/m2  d 1 – 4 CI 
E 30 mg/m2   d 1 – 4 CI 
Maintenance Year 1: 
 
[ 4 weeks to 4 months post Consolidation 2]  
 
 
 
 
Maintenance Year 2-3 
Treatment for 3 years: 
VRD 
V 1.0 mg/m2/wk  d 1, 4, 8, 11 
R 15 mg/d          d 1 – 20 
R  5 mg/d          d 21 – 28 
D 20 mg/wk  d 1-4 and 8-11 
 
 
VRD weekly 
V 1.0 mg/m2/wk  d 1, 8, 15, 22 
R 15 mg/d          d 1 – 20 
R  5 mg/d          d 21 – 28 
D 20 mg/wk  d 1, 8, 15, 22 
152 
 
Appendix G: List of Abbreviations 
ACS American Cancer Society 
ASCT (peripheral blood) Autologous Stem Cell Transplant 
AE adverse event 
B2M β 2 microglobulin 
BMH Andersen’s behavioral model of health services utilization  
BRAF v-raf murine sarcoma viral oncogene homolog B 
CBC complete blood count (hematology) 
Chem7 Basic metabolic panel (chemistry)  
CR complete response 
CRF case report form 
CT x-ray computed tomography 
CYP Cytochrome P 
DLT dose-limiting toxicity 
DWIBBS diffusion weighted imaging with background body signal suppression 
DVT/PE Deep Vein Thrombosis / Pulmonary Embolism 
EBMT European Group for Blood and Marrow Transplantation 
ECOG Eastern Cooperative Oncology Group 
ERK Extracellular signal-regulated kinase 
FDA Food and Drug Administration 
FLC free light chain 
GEP Gene expression profiling 
GEP70 Gene expression profiling of 70 genes related to multiple myeloma 
GWAS Genome-Wide Association Studies 
HRMM High Risk Multiple Myeloma 
ICF informed consent form 
ICH International Conference on Harmonization 
IFE Immunofixation electropheresis 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IMiD Immunomodulatory drug 
IMWG International Myeloma Working Group 
IRB Institutional review board 
kg kilogram 
KRAS kirsten rat sarcoma viral oncogene homolog 
LFT Liver function test 
LRMM Low Risk Multiple Myeloma 
MAPK mitogen-activated protein kinase 
MM Multiple myeloma 
MMDB Multiple Myeloma Database 
M-protein monoclonal protein 
MGUS Monoclonal Gammopathy of Undermined Significance 
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MIRT Myeloma Institute for Research and Therapy 
MR minor response 
MTD maximum tolerated dose 
MUGA Multi gate acquisition scan to assess cardiac function 
NCI National Cancer Institute 
NCI-CTCAE NCI Terminology Criteria for Adverse Events 
NDxMM Newly Diagnosed Multiple Myeloma 
NRAS neuroblastoma RAS viral oncogene homolog 
OMIM Online Mendelian Inheritance in Man database 
OS Overall Survival 
PCs Plasma Cells 
PET  positron emission tomography 
PFS Progression Free Survival 
PG Pharmacogenomics 
P-gp phosphoglycoprotein 
PHI protected health information 
PK Pharmacokinetics 
PR partial response 
PT Prothrombin time 
R/R MM relapsed/refractory multiple myeloma 
SAE serious adverse event 
sCR stringent complete response 
SMM Smoldering Multiple Myeloma 
SPEP serum protein electrophoresis 
TNF-α tumor necrosis factor α 
TT3 a/b Total Therapy 3 a/b 
UARK University of Arkansas for Medical Sciences 
UPEP urine protein electrophoresis 
VDT Velcade (bortezomib), Dexamethasone, Thalidomide (thalidomide) 
VDT-PACE Velcade (bortezomib), Dexamethasone, Thalidomide (thalidomide), 
cisplatin, doxorubicin, cyclophosphamide, etoposide 
VGPR very good partial response 
VIP Very Immunocompromised Patient (Protocol) 
VRD Velcade, Revlimid, Dexamethasone 
VTD Velcade, Thalidomide, Dexamethasone 
VMP Velcade, Melphalan, Dexamethasone 
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Appendix H: UARK IRB Approval Letter 
 
Institutional Review Board 
4301 West Markham, #636 
Little Rock, AR 72205-7199 
XXX-XXX-XXXX 
XXX-XXX-XXXX (fax) 
http://irb.uams.edu/  
 
FWA00001119  
 
04/03/2015  
 
PI Name: Miller, Scott 
 
PI Department: MYEL Myeloma Business Planning  
 
Protocol Number: 204088  
Protocol Title: UARK 2015-06: PFS and OS Analysis in Molecularly Defined Risk and 
Distance Traveled in Newly Diagnosed Multiple Myeloma  
NEW SUBMISSION APPROVAL, EXPEDITED 
 
 
The Institutional Review Board approved this study on 04/03/2015, based on Title 45 
CFR 46.110, using expedited review procedures under category 5.  
 
This approval period runs from 04/03/2015 to 04/02/2016  
 
The IRB determined the risk for adults who enter this study to be minimal.  
 
 
 
The IRB waived the requirement for obtaining informed consent.  
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The IRB granted a waiver of HIPAA authorization for the PHI described in the 
submission as follows:  
overall and progression-free survival, GEP70 defined risk status (high or low), distance 
from MIRT based on subject zip code at presentation, transplant status, age < 65, and 
molecular subgroup  
 
The IRB determined that the research cannot practicably be conducted without access to 
or use of this PHI, and cannot practicably be carried out without the waiver.  
 
The IRB determined that the research uses the following methods to ensure minimal risk 
to privacy of subjects:  
• A plan to protect the identifiers from improper use or disclosure. 
• A plan to destroy the identifiers at the earliest opportunity consistent with the 
conduct of research, unless there is a health or research justification for retaining 
the identifiers or retention is required by law. 
• An assurance that the PHI will not be re-used or disclosed to any other person or 
entity, except as required by law, for authorized oversight of the research project, 
or for other research as permitted by the HIPAA regulations. 
 
Reminder: All other HIPAA requirements, including Minimum Necessary Rule, still 
apply.  
 
Committee Notes/Comments:  
 
 
The following documents were received: 
• Protocol v2.03.31.2015 tracked (Type: Protocol) 
• Protocol v2.03.31.2015 clean (Type: Protocol) 
 
 
If you have any questions, please contact an IRB administrator at 501-686-5667. 
Click here to access study.  
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Appendix I: UARK IRB Approval Letter (Amendment 1) 
 
Institutional Review Board 
4301 West Markham, #636 
Little Rock, AR 72205-7199 
XXX-XXX-XXXX 
XXX-XXX-XXXX (fax) 
http://irb.uams.edu/ 
FWA00001119  
05/12/2015 
PI Name: Miller, Scott PI Department: MYEL Myeloma Business Planning  
Protocol Number: 204088  
Protocol Title: UARK 2015-06: PFS and OS Analysis in Molecularly Defined Risk and 
Distance Traveled in Newly Diagnosed Multiple Myeloma  
MODIFICATION APPROVAL, EXPEDITED  
The Institutional Review Board approved your 05/08/2015 modification on 05/12/2015, 
using expedited review procedures.  
Committee Notes/Comments:  
The following documents were approved:  
  • Protocol v3.05.06.2015 tracked (Type: Protocol)   
  • Protocol v3.05.06.2015 clean (Type: Protocol)  If you have any questions, please 
contact an IRB administrator at 501-686-5667.  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Appendix J: UARK PRMC Acknowledgement 
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Appendix K: UARK Waiver of Data Use Agreement 
A DUA is not required if there is a waiver of auth.  
 
Sent from my iPhone  
 
On Apr 15, 2015, at 9:16 AM, Wong Scoggins, Dori <DWong@uams.edu> wrote: 
David, 
  
Can you find out who funded (if any) Total Therapy 3a and b? 
  
I think the DUA is not needed if a waiver of HIPAA authorization was given. Jennifer, can you 
confirm? 
  
Dori 
  Dori Wong Scoggins, Esq. 
UAMS Office of Research & Regulatory Affairs 
Office: 501.526.6247  Fax: 501.686.8359  
ResearchServices.uams.edu 
  
From: Avery, David A  
Sent: Wednesday, April 15, 2015 8:25 AM 
To: Wong Scoggins, Dori; Holland, Jennifer R "Research" 
Cc: Miller, Scott EB 
Subject: IRB# 204088 
  
Dori/Jennifer, 
We had previously discussed whether a DUA might be needed for Scott’s study in order 
to share information with his dissertation committee at Walden University as detailed in 
Section VIII of the protocol.  The study was approved by expedited review on 4/3 with 
waiver of HIPAA authorization; therefore, I assume it was determined that a DUA is not 
required.  Can you please confirm this with a response to this email? 
  
Thanks, 
David 
  
David	  A.	  Avery 
Associate Director of Clinical Trials & Regulatory Affairs 
Myeloma Institute for Research and Therapy 
University of Arkansas for Medical Sciences 
4301 West Markham St., Slot 816 
Little Rock, AR 72205 
Telephone: 501.526.6990 ext. 2431 
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Appendix L: UARK Letter of Cooperation 
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Appendix M: Walden University IRB Approval 
From: IRB   
Date: Thursday, September 17, 2015 at 4:24 PM 
To: Scott Miller, IRB   
Cc: XXXXXXXX  
Subject: IRB Materials Approved - Scott Miller 
 
Dear Mr. Miller, 
  
This email is to notify you that the Institutional Review Board (IRB) confirms that your study entitled, 
"Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma," meets Walden 
University’s ethical standards. Our records indicate that the site’s IRB agreed to serve as the IRB of record 
for this data collection. Since this study will serve as a Walden doctoral capstone, the Walden IRB will 
oversee your capstone data analysis and results reporting. The IRB approval number for this study is 09-17-
15-0232203. 
  
This confirmation is contingent upon your adherence to the exact procedures described in the final version 
of the documents that have been submitted to XXXXXX as of this date. This includes maintaining your 
current status with the university and the oversight relationship is only valid while you are an actively 
enrolled student at Walden University. If you need to take a leave of absence or are otherwise unable to 
remain actively enrolled, this is suspended. 
  
If you need to make any changes to your research staff or procedures, you must obtain IRB approval by 
submitting  the IRB Request for Change in Procedures Form.  You will receive confirmation with a status 
update of the request within 1 week of submitting the change request form and are not permitted to 
implement changes prior to receiving approval.  Please note that Walden University does not accept 
responsibility or liability for research activities conducted without the IRB's approval, and the University 
will not accept or grant credit for student work that fails to comply with the policies and procedures related 
to ethical standards in research. 
  
When you submitted your IRB materials, you made a commitment to communicate both discrete adverse 
events and general problems to the IRB within 1 week of their occurrence/realization.  Failure to do so may 
result in invalidation of data, loss of academic credit, and/or loss of legal protections otherwise available to 
the researcher. 
  
Both the Adverse Event Reporting form and Request for Change in Procedures form can be obtained at the 
IRB section of the Walden website: http://academicguides.waldenu.edu/researchcenter/orec 
  
Researchers are expected to keep detailed records of their research activities (i.e., participant log sheets, 
completed consent forms, etc.) for the same period of time they retain the original data.  If, in the future, 
you require copies of the originally submitted IRB materials, you may request them from Institutional 
Review Board.  
  
Sincerely, 
Libby Munson 
Research Ethics Support Specialist 
Office of Research Ethics and Compliance 
Email: irb@waldenu.edu 
Fax: 626-605-0472 
Phone: XXX-XXX-XXXX 
Office address for Walden University: 
100 Washington Avenue South, Suite 900 
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Minneapolis, MN 55401 
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Appendix N: Permission for Use of Andersen Model 
From: Ron Andersen <XXXXXXXX@ucla.edu> 
Date: Monday, September 28, 2015 at 1:30 PM 
To: Scott Miller <scott.miller2@waldenu.edu> 
Subject: RE: Permission to use figures 
 
Dear Scott, 
  
You have my permission to use the figures in the “Revisiting the Behavioral Model” 
articles.  Best wishes for the successful completion of your dissertation. 
  
Ron Andersen 
  
From: Scott Miller [mailto:scott.miller2@waldenu.edu]   
Sent: Thursday, September 24, 2015 6:57 AM  
To: XXXXXXXXX@ucla.edu  
Cc: Scott Miller  
Subject: Permission to use figures 
  
Good Morning Dr. Andersen, 
  
My name is Scott Miller, I am a graduate student pursuing my terminal degree in public 
health.  I am seeking your permission to use figures from your article “Revising the 
Behavioral Model and Access to Medical Care: Does It Matter?” in my dissertation.  The 
dissertation will be both written and preserved electronically. 
  
The version of your model I have chosen appears in the Journal of Health and Social 
Behavior 1995, Vol. 36 (March): 1-10. 
  
I am aware that the model has been revised and published in a book chapter by 
Kominski.  I am happy to use the updated version if you prefer, although I do not think 
this is a critical change. 
  
Thank you for your consideration. 
  
Best regards, 
  
Scott 
  
Scott E. Miller 
Graduate Student 
Scott.miller2@waldenu.edu	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Appendix O: Permission for Use of Hajek figure	  
From: XXXXX <XXXXXXXXX > 
Date: Tuesday, September 29, 2015 at 5:05 AM 
To: Scott Miller <scott.miller2@waldenu.edu> 
Subject: Re: Permission to use a figure 
 
Hi Scott, 
 
You may reproduce the specified figure in your thesis as long as you follow the CC BY 
3.0 license terms. The preferred and most convenient way to do so is to make sure you 
cite the source chapter, and include the following notice in the figure caption: 
 
© 2013 Hajek R. Published in [short citation] under CC BY 3.0 license. Available from: 
http://dx.doi.org/10.5772/55366 
 
Contacting the author directly is not strictly required, but it's never a bad idea to notify 
authors about reproducing their work as a matter of courtesy. 
 
Please feel free to contact me if you have any additional questions or concerns regarding 
this matter. 
 
Kind regards, 
Sasa 
-- 
Sasa Marcan 
Library and Information Service Coordinator 
______________________________ 
InTech - open science | open minds 
Email: XXXXXXXX 
Website: http://www.intechopen.com 
Phone: +385 51 688 994 
Fax: +385 51 686 166 
 
Journal Department 
Janeza Trdine 9 
51000 Rijeka, Croatia 
 
The information contained in either this email and, if applicable, the attachment, are 
confidential and are intended only for the recipient. If you have received this 
communication in error, please notify us by e-mail XXXXXXX then delete the e-mail 
and all attachments and any copies thereof. This communication is part of InTech's 
publishing activity and is not intended for unauthorized use or distribution. 
 
